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CHAPTER 1 - INTRODUCTION 
1.1. The Pathogenesis of Acute Myocardial Infarction 
Acute myocardial infarction (AMI) results from a disruption of coronary blood flow to 
part of the heart, caused by the occlusion of a coronary artery. With an incidence of 935 in 
100,000 persons leading to 141,462 deaths in 2006, AMI remains the principal cause of mortality 
in the United States. In addition, AMI is associated with a heavy financial burden. The American 
Heart Association estimates the cost of treating coronary heart disease related injuries at $165.4 
billion for 2009 alone [1]. A prolonged ischemic event triggers several molecular and structural 
changes, which inevitably cause cardiac myocytes to be severely damaged or to die, further 
impairing myocardial function. Currently the treatment of AMI relies on reperfusion therapy 
based on inducing pharmacological (e.g. thrombolytics) and/or invasive reopening (e.g. 
angioplasty) of the occluded coronary artery. However, for the reperfusion therapy to be 
efficacious, it has to be started as soon as possible after the onset of ischemia [2]. If coronary 
flow is not re-established or is re-established after delay, post-ischemic cardiac cell loss and 
ventricular remodeling progress to heart failure in up to 40% of patients [3]. Paradoxically, the 
reintroduction of oxygen-rich blood to the ischemic tissue can have some deleterious effects, 
collectively referred to as “reperfusion injury”. Thus, the prevention of post-ischemic cardiac cell 
death may represent the best therapeutic modality to limit damage incurred by the myocardium.  
During the past decades, extensive investigation has led to the development of 
cardioprotective therapeutic strategies against ischemia-reperfusion (I/R) injury. The description 
of ischemic pre-conditioning [4], where multiple brief periods of ischemia protect the 
myocardium from a subsequent sustained ischemic insult, had a major impact in the field of 
cardioprotection. This has led to the discovery of the phenomenon of ischemic post-conditioning, 
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where repetitive bouts of ischemia are applied at the onset of reperfusion, which was also shown 
to protect the heart from myocardial I/R injury [5]. Considerable advances have been made in 
identifying the molecular mechanisms that underlie the protection afforded by these strategies. 
This has opened new venues for the identification of novel therapeutic agents that mimic the 
cardioprotective effects of ischemic pre- and post-conditioning (pharmacological pre- and post-
conditioning). In addition, pharmacological agents targeting key signaling effectors involved in 
the ischemic and reperfusion cascades have also been developed [6]. While the majority of these 
therapeutic strategies have proven to be efficient in protecting the heart against I/R injury in 
animal models, most of them have yielded disappointing results in clinical trials [7]. Despite 
these setbacks, new potential “druggable” targets for the clinical management of myocardial I/R 
injury keep emerging from the continued progress of our understanding of the pathogenesis of 
I/R injury.  
At the clinical level, myocardial injury is characterized by myocardial stunning, 
arrhythmia, microvasculature dysfunction and myocardial cell death [8]. Myocardial cell death is 
governed by the complex biochemical cascades set in motion by both ischemia and reperfusion 
[9] (Figure 1). In cardiomycoytes, ischemia induces a rapid depletion of ATP, acidosis and a 
dysregulation of ion homeostasis (extracellular hyperkalemia, intracellular accumulation of Na+, 
and cytosolic and mitochondrial build-up of Ca2+). Depending on the severity of the ischemic 
insult and its duration, these events can lead to the disruption of the plasma membrane and 
irreversible injury. Reperfusion triggers multiple events in the ischemic myocardium. The 
restoration of blood flow aggravates the alterations of ionic fluxes induced by ischemia. The 
Ca2+ overload is exacerbated by the enhanced accumulation of Na+. In addition, the 
reintroduction of oxygen triggers the production of reactive oxygen species (ROS). 
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Figure 1: Cellular mechanisms of cardiac ischemia-reperfusion injury. The sequence of 
events elicited by ischemia include: ATP depletion, production of lactic acid, H+ and CO2 
(anaerobic glycolysis) and acidification, overload of Na+ (Na+/H+ exchanger and inhibition of 
the Na+/K+ ATPase pump), build-up of Ca2+ in the cytosol and mitochondria (reversal of 
Na+/Ca2+ exchanger). In turn, reperfusion promotes the production of reactive oxygen species 
(ROS), restoration of a physiological pH (wash out of lactic acid, H+ and activation of Na+/H+ 
exchanger and Na+/HCO3- transporter), Ca2+ overload in cytosol, mitochondria and 
sarcoplasmic reticulum (reversal of Na+/Ca2+ exchanger), restoration of ATP production and 
opening of the mitochondria permeability pore (MPP) (oxidative stress, normal pH, Ca2+ 
overload). The morphological changes induced by I/R include: (i) cytoskeleton fragility, 
caused by the degradation of α-fodrin mediated by Ca2+-activated calpain, (ii) 
hypercontracture, which is caused by the ATP/cytosolic Ca2+ overload combination and can 
spread to adjacent cells, and (iii) rigor-contracture, which occurs when the ATP level is low (a 
slow ATP production recovery or damaged mitochondria). In addition, the opening of the 
MPP leads to loss of ATP, damage to the mitochondria, release of ROS and cytochrome c in 
the cytoplasm. Collectively, these events result in the physical disruption of the sarcolemma 
and cell death. 
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In parallel, oxidative stress, Ca2+ overload and the renormalization of the pH promote the 
opening of the mitochondrial permeability transition pore (MPP). This phenomenon results in the 
loss of the structural integrity and function of the mitochondria, ATP depletion, release of ROS 
and cytochrome c into the cytoplasm. The biochemical alterations elicited by ischemia-
reperfusion have major repercussions on the morphology of cardiac cells [10]. The recovery of 
ATP production combined with an elevated intracellular level of Ca2+ provokes excessive 
myofibrillary contractility (hypercontracture). This mechanical stress was shown to propagate to 
adjacent myocytes through gap junctions and to contribute to the final size of the infarct [11]. In 
addition, hypercontracture is enhanced by the cell fragility caused by the calpain-mediated 
degradation of α-fodrin, a key constituent of the membrane cytoskeleton [12,13]. The activation 
of calpain proteases requires Ca2+ and is repressed by acidic pH. The excessive activation of 
calpains occurs primarily during reperfusion when the level of Ca2+ is abnormally elevated and 
the pH is renormalized. These morphological changes collectively lead to the disruption of the 
sarcolemma and cell death. 
Myocardial injury can progress along two distinct cell death pathways - necrosis and 
apoptosis [14]. Necrosis develops in response to lethal exogenous stimuli under pathological 
conditions. Necrotic cell death is characterized by cell swelling, rupture of the cell membrane 
with release of cellular components (creatine kinase, troponin) and subsequent inflammation. In 
contrast, apoptosis (programmed cell death type I) can be triggered in response to physiological 
or pathological stimuli that are endogenous or exogenous to the cell. Apoptosis is an ATP-
dependent process that progresses through a well-orchestrated series of molecular, biochemical, 
and morphological events that do not provoke an inflammatory response. The relative 
contribution of necrosis and apoptosis to the total cardiac cell loss following both ischemia and 
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reperfusion is not well established. The degree of ATP depletion appears to be a determinant 
factor in the mode of death that injured myocytes will undergo [15]. In the infarct core, which is 
completely deprived in oxygen and energy, myocytes die by necrosis. In contrast, in the peri-
infarct penumbra which is hypoxic, myocardial cell death occurs via both apoptosis and necrosis 
[16]. Necrosis represents the predominant mechanism of myocyte death during ischemia. 
However, the occurrence of this process was also observed during the reperfusion phase. The 
presence of necrotic cells was detected in the infarct early following the restoration of blood flow 
but also 24 hours post-reperfusion. Also, apoptosis has been reported to occur in the majority of 
the injured rat cardiomyocytes during the first hours after coronary occlusion (i.e. ischemia) [17]. 
Conversely, Gottlieb and colleagues have observed the presence of apoptotic cells in reperfused 
but not in ischemic rabbit hearts [18]. Interestingly, evidence also pointed to a step-wise 
progression of the apoptotic program where apoptosis could be initiated during ischemia and 
completed during reperfusion [19-21]. The discrepancy in these findings may be due to the wide 
variety of experimental models. Each model has different technical limitations in its ability to 
estimate the incidence and timing of necrosis and apoptosis [22].  The picture of myocardial cell 
death was further complicated by the observation that autophagy is involved in the pathogenesis 
of myocardial I/R injury.  
1.2. The Process of Autophagy and its Significance in the Heart 
 Macroautophagy (hereafter autophagy) is an evolutionarily conserved catabolic process 
that targets dysfunctional or damaged cytoplasmic constituents to the lysosome for degradation 
and recycling. Autophagy occurs constitutively in all eukaryotic cells where it operates as a 
metabolic homeostatic mechanism [23]. Autophagy can be further activated in response to 
various physiological and pathological stimuli to either promote cell survival (e.g. starvation, 
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oxidative stress [24]), or to act as a mode of cell death, type II programmed cell death (e.g. 
during development) [25]. Autophagy progresses through several steps orchestrated by a set of 
molecular effectors, the autophagy related genes (Atg) proteins (Figure 2). Upon induction, 
autophagy starts with the appearance of a small isolation membrane, the phagophore, which 
engulfs parts of the cytoplasm and elongates to form a double-membrane vesicle called the 
autophagosome. The latter undergoes a maturation process and ultimately fuses with a lysosome 
to form the autophagic vacuole (or autolysosome). The vesicular contents is degraded by 
lysosomal hydrolases, thereby providing the cell with a new source of amino acids, lipids and 
sugars for energy production. The formation of the autophagosome is initiated by the class III 
phosphoinositide 3-kinase (PI3-K) protein complex that includes Beclin 1 (Atg6) and involves 
two ubiquitin-like conjugation systems which result in the formation of Atg5-Atg12 and LC3-
phosphatidylethanolamine (LC3-II) [26]. While the molecular mechanisms involved in each step 
of the autophagic process are well understood, a debate persists in the field over the origin of the 
phagophore. The endoplasmic reticulum (ER), the trans golgi network (TGN) and the 
mitochondria have been proposed as possible sources of autophagosomal membranes [27]. A 
recent study has provided strong evidence that in normal rat kidney cells, the autophagosomal 
membranes originate from the outer membrane of mitochondria during starvation but not under 
ER-stress conditions [28]. Whether this phenomenon can be observed in other cell types and 
under other stress conditions such as ischemia, awaits further studies. Nonetheless, this study has 
unraveled a new interplay between autophagy and the mitochondrion.  
Autophagy is under the control of multiple signaling pathways [29] (Figure 3). The 
kinase mTOR (mammalian Target Of Rapamycin) is a key modulator of autophagy. mTOR is a 
sensor of nutrients and is repressed under conditions of nutrient deprivation and hypoxia. 
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Repression of mTOR promotes increased autophagic activity. mTOR receives multiple inputs 
from metabolic processes and growth factors. Under conditions of growth, mTOR activity is 
enhanced by factors that activate the class I PI3-K/Akt pathway, which inhibits TSC1/TSC2 and 
finally increases the activity of Rheb, a GTPase required for mTOR activity. The stimulation of 
this cascade results in the inhibition of autophagy. mTOR is also regulated by the adenosine 
monophosphate-activated protein kinase (AMPK), a sensor of the intracellular AMP/ATP ratio. 
AMPK is activated in response to elevated intracellular content of AMP caused by ATP 
hydrolysis. AMPK represses mTOR activity leading to activation of autophagy. Autophagy is 
modulated by other signaling pathways that are independent of mTOR. Zhang and colleagues 
have demonstrated that prolonged hypoxia induced mitophagy to promote mouse embryonic 
fibroblasts (MEF) survival. This process was mediated via activation of hypoxia inducible factor 
1α (HIF-1α) and required the presence of BNIP3 and autophagy proteins including Beclin 1 and 
Atg5 [30]. A recent study has shown that under starvation conditions, the p110-β catalytic 
subunit of the Class I PI3-K could directly promote the stimulation of autophagy in MEF, in the 
liver and heart through its association with the Class III PI3-K initiation complex. This 
autophagy-promoting role of p110-β was independent of its kinase activity and Akt activation 
[31]. Depnding on the downstream target, the growth factor-mediated activation of the Ras 
signaling pathway either activates or inhibits autophagy. In NIH3T3 mouse fibroblasts, 
activation of the Class I PI3-K cascade by Ras results in inhibition of autophagy [32]. In contrast, 
the Ras-mediated activation of the Raf-1–MEK1/2–ERK1/2 signaling cascade in response to 
amino acid depletion promotes autophagy [33]. Finally, DAPk and DRP-1, two members of the 
Ca2+/calmodulin-regulated Serine/Threonine death kinases family, were found to be necessary 
for the induction of autophagic programmed cell death (type II) in HeLa and MCF-7 cancer cells 
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subjected to multiple stimuli including amino acids depletion [34]. In a recent study, DAPk was 
shown to promote the initiation of autophagy by phosphorylating Beclin 1, which is subsequently 
released from the pro-apoptotic Bcl-2/Bcl-XL complex [35,36]. 
Autophagy plays a crucial role in the heart [37]. The occurrence of autophagy in cardiac 
myocytes was reported for the first time in 1976 by Sybers and co-workers [38]. Because cardiac 
myocytes are terminally differentiated and unable to renew themselves, they rely on autophagy 
to maintain their viability and functionality. Cardiac myocytes have a high requirement in energy 
(ATP) which is reflected in an abundance of mitochondria. Mitophagy, a process responsible for 
the removal of damaged and dysfunctional mitochondria through autophagy, represents a key 
mechanism in the survival of cardiomyocytes. The presence of mitochondria in autophagosomes 
in cardiomyocytes exposed to various stress conditions was reported by several groups [38-40]. 
The significance of the autophagic process in the healthy heart has also been emphasized in 
several studies. A defect in the degradation phase of autophagy, resulting from a deficiency of 
LAMP2, a lysosomal membrane protein, induced severe cardiac dysfunction in patients and mice 
[41,42]. Most importantly, the deficiency in Atg5 expression in the heart of adult mice resulted 
in the development of cardiac hypertrophy, left ventricular dilation and contractile dysfunction 
[43]. Autophagy has been shown to be altered in various cardiac pathologies including 
myocardial hypertrophy, cardiomyopathies, and ischemic heart disease [44]. However, the role 
played by autophagy in the pathogenesis of these conditions is not clearly established.  
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Figure 2: The process of autophagy. Autophagy is initiated with the formation of the 
phagophore, mediated by the class III PI3-K complex that includes Vps34, Vps15, Atg14 and 
Beclin 1 (a) and progresses through a succession of steps: (1) elongation of the phagophore 
and engulfment of cytoplasmic material targeted for degradation, (2) formation of the 
autophagosome, with delipidation of LC3-II by Atg4, (3) fusion of the autophagosome with  
the lysosome to form the autolysosome, (4) degradation of the vesicle content by lysosomal 
hydrolases and  (5) recycling of the degradation products (amino acids, lipids and sugars) for 
ATP production. The autophagy machinery consists of two conjugation systems required for 
the elongation and extension of the phagophore: Atg5-Atg12, which subsequently 
oligomerizes with Atg16 (b), and LC3-phosphtidylethanolamine, LC3-II. LC3-II is formed as 
a result of the Atg4-mediated cleavage of cytosolic LC3. The resulting form of LC3, LC3-I is 
subsequently conjugated to a single phosphatidylethanolamine (PE) molecule to form LC3-II, 
a reaction mediated by Atg3 and Atg7 (c).    
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Figure 3: The regulation of autophagy Autophagy is regulated by multiple signaling 
pathways. In response to growth factors, mTOR is activated by the class I PI3-K and Akt, 
which inhibits TSC1/TSC2. The activation of this cascade leads to the inhibition of 
autophagy. mTOR activity is inhibited by AMPK, a kinase activated in response to elevated 
intracellular AMP/ATP ratio. In addition, the p110-β catalytic subunit of the class I PI3-K can 
directly stimulate autophagy during starvation, independently of Akt activation, through its 
association with the Class III PI3-K complex. The growth factor-mediated activation of Ras 
induces antagonistic effects on autophagy depending on its downstream target – while the 
activation of the Class I PI3-K cascade represses autophagy, the stimulation of the Raf-1–
MEK1/2–ERK1/2 signaling cascade in response to amino acid depletion promotes autophagy. 
Hypoxia induces autophagy via activation of the hypoxia-inducible factor 1α (HIF-1α). 
Finally, autophagy is also regulated by the DAPk, which promotes the initiation of autophagy 
through the release of Beclin 1 from the Bcl-2/Bcl-XL complex. The DAPk-related protein 
kinase 1 (DRP-1) was also found to be necessary for the induction of autophagy. 
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1.3. Autophagy in Myocardial Ischemia-Reperfusion Injury  
The modulation and the role of autophagy during myocardial I/R injury have been 
extensively investigated. An increase in autophagosomes in cardiomyocytes following I/R injury 
has been reported by several groups and became a hallmark of myocardial I/R injury. However, 
the nature of the role of autophagy during myocardial I/R injury is highly controversial. 
Presently, autophagy is portrayed either as a cardioprotective mechanism or a contributor to cell 
death. The conflicting findings regarding the function of autophagy may stem from several 
experimental parameters. The process of autophagy has been investigated in multiple 
experimental models (in vitro, ex vivo and in vivo) and species (rat, pig, rabbit and mouse). As 
the degree of complexity of the model increases, it becomes virtually impossible to extrapolate 
results obtained from cultured cells to isolated hearts to the intact heart. Additional variables 
such as the intensity/duration of the ischemic insult and the methodology used to assess the 
occurrence and the function of autophagy may further complicate the picture. 
A large array of data has been obtained from in vivo studies carried out in rodent and 
swine models of myocardial I/R injury. In a swine model of chronic myocardial stunning, Yan 
and co-workers [45] observed an increase in autophagy in the heart of pigs subjected to six 
episodes of ischemia and subsequent reperfusion. An inverse correlation between the occurrence 
of autophagy and apoptosis was reported. In their study, Matsui et al. [46] have reported an 
induction of autophagy in the hearts of mice subjected to 20 minutes of global ischemia. 
Furthermore, autophagy was enhanced after 20 minutes of reperfusion. The use of beclin 1+/- 
mice allowed them to demonstrate that autophagy plays opposite roles during I/R injury. That is 
autophagy protected the heart during ischemia and promoted myocyte death during reperfusion 
and these effects were mediated by AMPK and Beclin 1, respectively. In the same line of 
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evidence, Noh and co-workers [47] have recently shown that autophagy was also enhanced in the 
hearts of rats subjected to 25 minutes of global ischemia followed by 24 hours of reperfusion. In 
this study, the administration of propofol, an intravenous anesthetic drug, during I/R reduced 
both the myocardial infarct size and the level of autophagy. This result suggested that autophagy 
was detrimental during myocardial I/ R injury. In most of the aforementioned studies, autophagy 
was found to be enhanced in the hearts of animals following both phases of I/R injury. In a 
recent study, French and colleagues [48] have reported the absence of autophagic structures in 
the infarcted zones of hearts from transgenic GFP-LC3 mice subjected to persistent ischemia (24 
hours) or to ischemia (1, 4 hours) followed by 24 hours of reperfusion. In addition, the level of 
autophagosomes was reduced in the peri-infarct zones of ischemic hearts. The reduction in 
autophagy was further evidenced by a decrease in the LC3-II/LC3-I ratio and an up-regulation of 
mTOR activity in myocytes. To gain some insights into the role played by autophagy during 
myocardial I/R injury, the investigators used drugs that mimic the protective action of pre-
conditioning such as hydrogen sulfide (an endogenous gasotransmitter) and chloramphenicol 
succinate (an inhibitor of cytochrome P450 monooxygenase, mitochondrial protein synthesis, 
and a bacteriostatic antimicrobial). The data derived from these studies were inconsistent. The 
infusion of hydrogen sulfide during I/R reduced the myocardial infarct size in pigs. This effect 
was accompanied by a decrease in mTOR activation and Beclin 1 expression in myocytes [49]. 
The administration of chloramphenicol succinate as a pre-treatment or during reperfusion 
protected the pig heart from I/R injury. In contrast, the cardioprotective effect of 
chloramphenicol succinate was associated with an increase in the expression of LC3-II and 
Beclin 1 [50].   
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Autophagy has also been studied in isolated hearts. In 1980, Decker and colleagues 
reported an induction of autophagy in Langendorff perfused rabbit hearts subjected to both 
ischemia and reperfusion. The majority of cardiac myocytes from rabbit hearts subjected to 1 
hour of ischemia and 1 hour of reperfusion was irreversibly injured and contained non-functional 
lysosomes. On the other hand, shorter periods of ischemia (20 and 40 minutes) followed by 1 
hour of reperfusion resulted in an improved contractility of cardiac myocytes concomitant with 
an increased presence of autophagic vacuoles. In this study, the increase in autophagy correlated 
with functional recovery and salvage of the myocardium after I/R, suggesting a cardioprotective 
role of autophagy against I/R injury [39,51]. The effect of cardioprotective drugs on the 
autophagic response elicited by I/R in isolated hearts was also investigated. For example, 
sulphaphenazole (an inhibitor of cytochrome P450 monooxygenase and an antimicrobial agent) 
pre-treatment of rat hearts subjected to 30 minutes of ischemia and 2 hours of reperfusion 
reduced the infarct size and increased autophagy. Using the same model, several groups have 
shown that pre-treatment with small doses of resveratrol alone or in combination with γ-
tocotrienol, or Longevinex (a modified resveratrol) protected the heart against I/R injury. The 
cardioprotection afforded by these treatments was associated with an up-regulation of autophagy 
[52-54]. 
A large body of experimental work demonstrating the involvement of autophagy in the 
pathogenesis of I/R injury has been carried out in cultured cardiac cells. These efforts have been 
directed towards the development of experimental conditions that recapitulate the changes 
(extra- and intra-cellular) elicited in the heart by ischemia. Thus, the model of simulated 
ischemia-reperfusion (sI/R) has been used by several groups and it has been valuable in 
identifying key biochemical and cellular events underlying the pathogenesis of myocardial I/R 
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injury. According to the experimental context, this basic model can differ in several aspects: the 
use and formulation of the “ischemia buffer”, the level of oxygen (anoxia, hypoxia), the duration 
of ischemia and reperfusion, and the cellular model (primary cultures of isolated neonatal or 
adult cardiac myocytes, immortalized cardiac cell lines such as HL-1). Valentim et al. have 
reported that autophagy can contribute to the demise of cardiac cells following sI/R injury. They 
observed an increase in autophagosomes (acidic vacuoles positively marked for 
monodansylcadaverine or lysotracker) in primary cultures of both neonatal and adult rat 
cardiomyocytes exposed to 4 hours of simulated ischemia (2.0% O2) followed by 16 hours of 
reperfusion. Inhibition of autophagy achieved by treatment with 3-methyladenine (3-MA) an 
inhibitor of autophagy by inhibition of PI3 kinases [55] or down-regulation of Beclin 1 reduced 
both the percentage of myocytes undergoing autophagy and cell death after sI/R [56]. In contrast, 
Hamacher-Brady and colleagues have examined the effect of sI/R on autophagy and shown its 
cardioprotective effect against sI/R on several occasions [57,58]. They have demonstrated that 
HL-1 cells exposed to 2 hours of simulated ischemia, achieved by incubating HL-1 cells in an 
“ischemia buffer” in the absence of oxygen, exhibited a low level of autophagy. The subsequent 
reperfusion of ischemic cardiac cells induced a partial reactivation of the autophagic process 
evidenced by the increase in autophagosomes after 1.5 and 3 hours. Treatments with either 3-MA 
or wortmannin, down-regulation of Beclin 1 or over-expression of Atg5K130R (a dominant 
negative mutant of Atg5) sensitized HL-1 cardiac cells to sI/R-induced apoptotic cell death. In 
addition, 2-chloro-N(6)-cyclopentyl adenosine (CCPA), a selective agonist of the adenosine 
receptor A1 that has cardioprotective properties, attenuated sI/R-induced cell death, presumably, 
through induction of autophagy.  
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1.4. Sildenafil and Myocardial Ischemia-Reperfusion Injury 
Numerous studies carried out in animal models of I/R injury have demonstrated the 
cardioprotective action of sildenafil citrate. Sildenafil (Viagra) is a potent and selective inhibitor 
of cGMP specific phosphodiesterase-5 (PDE5) and is currently licensed for the treatment of 
erectile dysfunction and pulmonary hypertension. PDE5 catalyzes the degradation of cyclic 
guanosine monophosphate (cGMP) and its inhibition by sildenafil enhances cGMP 
accumulation, which, in turn, causes vasodilatation in the corpus cavernosum. PDE5 is highly 
expressed in a large variety of tissues including platelets and smooth muscle of the systemic 
vasculature [59]. Although the expression of PDE5 in canine and mouse hearts has been 
reported, it is not clear whether PDE5 is present in human cardiomyocytes. Several studies have 
documented potent, acute and delayed cardioprotection afforded by sildenafil in in vitro, ex vivo 
and in vivo models of myocardial I/R injury [60]. This PDE5 inhibitor was shown to attenuate 
cardiac I/R injury through several mechanisms (Figure 4) including: (i) enhancement of nitric 
oxide (NO) generation resulting from increased expression of endothelial/inducible nitric oxide 
synthase (eNOS/iNOS) [61], (ii) activation of protein kinase C (PKC) which is translocated from 
the cytosol to the plasma membrane [62], (iii) opening of mitochondrial KATP channels [63], (iv) 
preservation of the mitochondrial membrane potential and NO-dependent up-regulation of 
Bcl2/Bax ratio [64], and (v) activation of cGMP-dependent protein kinase G (PKG) [65]. 
Sildenafil has also been shown to mediate its cardioprotective effect via up-regulation of ERK1/2 
phosphorylation, which was shown to occur in a PKG-dependent manner. Moreover, it has been 
reported that ERK1/2 mediates sildenafil-induced up-regulation of iNOS/eNOS, Bcl-2 and 
inactivation of glycogen synthase kinase 3β (GSK3β) [66]. In addition, a recent study has shown 
that the administration of sildenafil during the first 10 minutes of reperfusion after 30 minutes of   
  
16
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: Mechanisms of cardioprotection by sildenafil. Sildenafil inhibits the 
phosphodiesterase-5 (PDE5), which catalyzes the degradation of cyclic guanosine 
monophosphate (cGMP), resulting in the accumulation of cGMP in the cell. The 
cardioprotection afforded by sildenafil against I/R injury is mediated by several mechanisms. 
The activation of cGMP-dependent protein kinase G (PKG) mediates the upregulation of 
ERK1/2 activity, which in turn can lead to the upregulation of iNOS/eNOS, Bcl-2 and 
inactivation of glycogen synthase kinase 3β (GSK3β). The activation of the mitochondrial 
KATP channels mediated by Bcl-2 and GSK3β can prevent the opening of the mitochondrial 
permeability transition pore (MPP), thereby preserving the mitochondrial membrane potential. 
In parallel, sildenafil can induce the activation of protein kinase C (PKC) which is 
translocated from the cytosol to the plasma membrane. In addition, sildenafil triggers the 
phosphorylation of phospholemman (PLM) at position Ser69, which leads to the activation of 
its downstream target, the Na+/K+-ATPase in a PKC-dependent manner. These effects limit 
the ATP depletion and the influx of calcium in the cell, two major contributors of cell injury. 
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global ischemia protected isolated mouse hearts against infarction. This effect was shown to be 
mediated by the phosphorylation of phospholemman (PLM), a type 1 transmembrane protein, at 
position serine 69, which leads to the activation of its downstream target, the Na+/K+-ATPase in 
a PKC-dependent manner [67]. While sildenafil has been previously shown to reduce necrotic 
and apoptotic cardiac cell death induced by I/R, its effect on autophagy and the associated 
underlying signaling mechanism have never been investigated. 
1.5. Specific Aims 
The experiments described in this dissertation were designed to clearly establish the 
relationship between autophagy and myocardial injury. The central hypothesis is that autophagy 
is a beneficial process in cardiomyocytes and that the paucity of ATP may limit its occurrence 
during I/R. To test this hypothesis, it was necessary to develop a valid in vitro model of 
myocardial I/R injury, referred to as Hypoxia-Reoxygenation. In our model, ischemia 
(“hypoxia”) was mimicked by incubating murine atrial-derived HL-1 myocytes [68] in an 
ischemia buffer in presence of two different concentrations of oxygen – 0.5% and 2.0%. 
Reperfusion (“reoxygenation”) was achieved by restoring normal conditions of growth. Thus, 
our primary objective was to determine whether our model recapitulated the cellular events 
encountered in the ischemic myocardium. Consistent with this, we have focused on establishing 
the bioenergetic status of HL-1 cells following both ischemia and reperfusion. ATP depletion is a 
key feature of ischemia and is caused by the inhibition of the mitochondrial metabolic processes 
(oxidative phosphorylation and glycolysis) owing to the lack of oxygen. Although, reperfusion 
reactivates the production of ATP in the ischemic myocyte, the replenishment of ATP stores can 
be hampered by damage to the mitochondria elicited during reperfusion. In addition, the degree 
of ATP depletion is a determining factor in the mode of cell death that injured myocytes will 
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undergo. Accordingly, it was also essential to estimate cell death as an index of the validity of 
our model. The second objective of this project was to study the modulation and role of 
autophagy in HL-1 cardiomyocytes during ischemia alone or followed by reperfusion. Finally, 
this model was used to test the effect of sildenafil citrate, a cardioprotective agent, on the 
alterations of autophagy elicited by both I/R. 
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CHAPTER 2 – MATERIALS AND EXPERIMENTAL METHODS 
2.1. Materials 
The Claycomb medium, fibronectin, fetal bovine serum (FBS), norepinephrine, 2-
deoxyglucose, 3-methyladenine, aprotinin, phenylmethylsulfonyl fluoride (PMSF), bovine serum 
albumin and all of the chemicals not otherwise stated were from Sigma-Aldrich. L-glutamine, 
antibiotics, trypsin, 1X phosphate-buffered Saline (PBS) and 0.4% Trypan blue were obtained 
from Invitrogen. Okadaic acid, pepstatin, leupeptin, E64d, bafilomycin A1, pepstatin A methyl 
ester and cell-permeant E64d (EST) were all purchased from Calbiochem. Sildenafil citrate was 
kindly provided by Pfizer. The bicinchoninic acid (BCA) protein assay kit and the West-Pico 
chemiluminescence detection system were purchased from Pierce. The ATPlite assay kit was 
acquired from PerkinElmer Life Sciences. The Trans-Blot pure nitrocellulose membrane, 30% 
acrylamide/bisacrylamide solution, 10X Tris Buffered Saline (TBS), 10X Tris-Glycine-SDS, 
10X Tris-Glycine electrophoresis buffers and the precision plus protein kaleidoscope standards 
were all purchased from Bio-Rad Laboratories.  
The following antibodies were used for western blot analysis: rabbit anti-LC3 (1:2,500) 
was a gift of Dr. David Kessel (Wayne State University); rabbit anti-pan Akt (1:3,000), rabbit 
anti-phospho-Akt Ser473 (1:2,000), rabbit anti-mTOR (1:2,000), rabbit anti-phospho-mTOR 
Ser2448 (1:500), rabbit anti-AMPKα (1:1,000), rabbit anti-phospho-AMPKα Thr172 (1:2,000) 
were all purchased from Cell Signaling Technology; goat anti-actin (1:500), rabbit anti-ERK1 
(1:1,000), mouse anti-phospho ERK (1:1,000), rabbit anti-beclin 1 (1:2,000), rabbit anti-PDE5a 
(1:1,000) and the horseradish peroxidase (HRP)-labeled goat anti-rabbit (1:2,000), goat anti-
mouse (1:1,000) and donkey anti-goat (1:2,000) secondary antibodies were all purchased from 
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Santa Cruz Biotechnologies, Inc. All antibodies used for Western blot analyses were 
characterized for their specificity and optimal concentration.   
 
2.2. HL-1 Cell Culture Conditions 
The immortalized murine atrial derived-HL-1 cardiac cell line was a gift of Dr. Claycomb 
(Louisiana State University) [68]. The cells were maintained in Claycomb medium supplemented 
with 10% fetal bovine serum (FBS), 0.1 mM norepinephrine, 2 mM L-glutamine and 100 
units/mL penicillin/streptomycin. Cell cultures were maintained in a humidified incubator at 
37°C in an atmosphere of 5% CO2/95% air and sub-cultured (1:3 ratio) every 3 days. Flasks and 
Petri dishes used for HL-1 cell culture were pre-coated overnight at 37°C with sterilized 0.02% 
gelatin and 0.1% fibronectin (200:1) 
 
2.3. Hypoxia-Reoxygenation Model 
For simulation of ischemia, the medium of HL-1 cardiomyocytes was replaced with the 
ischemia buffer (118 mM NaCl, 1 mM NaH2PO4, 16 mM KCl, 2.5 mM CaCl•2H2O, 24 mM 
NaHCO3, 20 mM HEPES, 10 mM 2-deoxyglucose, and 20 mM sodium lactate, pH 6.8). This 
buffer was derived from the Esumi ischemia buffer [69] and was formulated to mimic the 
extracellular environment and the reduced intracellular energy state that occur in ischemic 
myocardium in vivo. The buffer contains 2-deoxyglucose, a glucose analogue unable to undergo 
glycolysis, which ultimately inhibits cellular metabolism. In addition, the buffer contains a high 
concentration of potassium (mimicking extracellular hyperkalemia) and has an acidic pH. To 
induce hypoxia, the cells were transferred to a sealed chamber placed in humidified incubator at 
37 °C in an atmosphere of 0.5% or 2.0% O2, 5% CO2 balanced with N2 for the time indicated. 
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The levels of O2 and CO2 present in the chamber were controlled by the OxyCycler (model C-40, 
BioSpherix, Ltd.) which sits outside the incubator and is attached to the chamber by umbilicals 
with actuator pods on the ends. The OxyCycler remotely senses the O2 concentration in the 
chamber and infuses N2 to lower concentration to reach the setpoint.  
After completion of the ischemic treatment, HL-1 cells were washed twice with PBS and 
complete growth medium was added to the cells. The ischemic cardiac cultures were returned to 
a humidified incubator at 37°C in an atmosphere of 5% CO2/95% air for the indicated period of 
reoxygenation to simulate reperfusion.  
 
2.4. Preparation of Cellular Extracts 
HL-1 cells were washed twice with ice-cold PBS and scraped while the dish was held on 
ice into RIPA buffer (50 mM Tris, 150 mM NaCl, 1 mM EDTA, 1% NP-40 and 0.25% sodium 
deoxycholate, pH 7.4) containing inhibitors of phosphatases and proteases (1 mM PMSF, 1 mM 
sodium orthovanadate, 1 mM sodium fluoride, 50 nM okadaic acid, 10 µg/mL aprotinin, 5 
µg/mL pepstatin, 10 µg/mL leupeptin and 5 µg/mL E64d). The cell suspension was incubated for 
15 min on ice. Insoluble material was removed by centrifugation at 14,000 rpm for 10 min. The 
resulting whole cell lysate was transferred to fresh tubes and kept on ice for immediate use or 
placed at -80°C for longer storage. Protein concentrations were determined using the BCA 
protein assay.  
 
2.5. Western Blot Analysis 
Sodium Dodecyl Sulfate (SDS) loading buffer was added to 40 µg of HL-1 cellular 
extract. The samples were heated for 5 min at 95°C and resolved by SDS-polyacrylamide gel 
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electrophoresis (PAGE). The profile of LC3 processing was determined by SDS-18% PAGE. 
The detection of mTOR (total and phosphorylated form) was performed with 7% gels. SDS-10% 
polyacrylamide gels were used to detect all other proteins. The fractionated proteins were 
transferred to nitrocellulose membrane in 25 mM Tris-HCl, 192 mM glycine and 20% methanol 
at 100V for 40 min to 105 min. Nonspecific binding sites were blocked with 5 % non-fat dry 
milk in TBS-T (20 mM Tris-HCl, pH 7.5, 500 mM NaCl, and 0.1% (v/v) Tween-20) for 1 hour 
at room temperature or overnight at 4°C. The membrane was washed twice with TBS-T and 
incubated with the primary antibody diluted in TBS-T for 1 hour at room temperature with 
shaking. The excess antibody was removed by washing the membrane with TBS-T three times 
for 5 min at room temperature. The immunoblot was incubated with the appropriate horseradish 
peroxidase labeled secondary antibody, diluted in TBS-T containing 5% non-fat dry milk, for 1 
hour at room temperature with shaking. The membrane was then washed three times for 5 min at 
room temperature. The West-Pico chemiluminescence detection system was used to visualize the 
immunoreactive bands by autoradiography, according to the manufacturer’s instructions. The 
autoradiographic films were scanned using an Epson photoscanner and protein band intensities 
were analyzed by densitometry and quantified using the free open source software ImageJ 
(http://rsb.info.nih.gov//ij/). The level of expression of the protein of interest was normalized to 
the level of actin or β-tubulin (loading control). 
 
2.6. Autophagy Assessment  
Autophagy was assessed by measuring the endogenous level of LC3-II by Western 
blotting. In higher eukaryotes, LC3-II is the only known protein that specifically associates with 
autophagosomes and autolysosomes and is therefore commonly used as a marker of autophagy 
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[70]. Upon activation of autophagy, LC3 is cleaved at its C-terminus by Atg4 to yield LC3-I, 
which is subsequently conjugated to a single phosphatidylethanolamine (PE) lipid molecule to 
form LC3-II. The latter is relocated to the membrane of the autophagosomes that fuse with the 
lysosomes. LC3-II is found at the luminal and cytosolic surfaces of autophagosomes. While the 
luminal pool is degraded after fusion with the lysosome, cytosolic LC3-II can be delipidated and 
recycled. Although both forms of LC3 have almost the same molecular weight, their 
electrophoretic properties differ. LC3-II (apparent 14 kDa) exhibits faster mobility than LC3-I 
(apparent 16 kDa) on SDS-PAGE. LC3 forms I and II can be differentially recognized by the 
LC3 antibodies. Thus, the endogenous levels of LC3-II (relative to a loading control rather than 
to LC3-I) measured by Western blotting reflects the number of autophagosomes in the cells at a 
given time. However, as LC3-II is degraded after the autophagosome fuses with the lysosome, 
the net level of LC3-II will not reflect the level of autophagy. This issue can be circumvented by 
preventing the lysosomal degradation of LC3-II, so that it accumulates in the cells [71]. This can 
be achieved by either (1) neutralizing the lysosomal pH with bafilomycin A1 (Baf A1), a proton 
pump inhibitor, or (2) inhibiting the lysosomal proteases with E64D and pepstatin A methyl ester 
or (3) a combination of both. In the course of our studies, it was found that the incorporation of a 
lysosomal inhibitor cocktail (LIC) containing 100 nM Baf A1, 5 µg/mL E64D (inhibitor of 
cysteine proteases including cathepsin B) and 5 µg/mL pepstatin A methyl ester (cathepsin D 
inhibitor) into HL-1 cardiac cultures for 2 hours was efficient in preventing the degradation of 
LC3-II as assessed by Western blotting. However, the LIC or the corresponding concentration of 
DMSO (vehicle, 0.2%) induced a significant increase in the level of cell death measured by flow 
cytometric analysis of Annexin V and propidium iodide (PI) stained cells (Figure 5), indicating 
that the LIC was highly cytototoxic. Therefore, we have examined the optimal conditions of Baf 
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A1 treatment that resulted in a maximal accumulation of LC3-II without inducing any 
cytotoxicity. The dose-response study indicated that the incubation of HL-1 cells for 2 hours 
with 25 nM Baf A1 resulted in a maximal accumulation of LC3-II detected by Western blotting. 
Interestingly, higher doses of Baf A1 reduced the level of LC3-II accumulation in HL-1 cells. 
This effect was in part due to the elevated concentration of the vehicle, as HL-1 cells treated for 
2 hours with increasing doses of DMSO alone exhibited lower levels of LC3-II. These results 
suggested that DMSO either countered the action of Baf A1 or inhibited autophagy. In addition, 
Baf A1 (25 nM) and the corresponding concentration of DMSO (vehicle, 0.025%) had no effect 
on the levels of necrotic or apoptotic cells measured by flow cytometry analysis of Annexin V 
and PI labeled cells (Figure 5). Thus, in our studies the degradation of LC3-II was prevented by 
adding 25 nM Baf A1 (in 0.025% DMSO) to the cardiac cultures for a maximum period of 2 
hours. The autophagic flux is commonly determined by comparing the LC3-II levels in the 
presence (cumulative LC3-II) and absence (instantaneous LC3-II) of lysosomal degradation. 
However, this approach requires that autophagy is under steady-state (i.e. LC3-II synthesis and 
degradation are equal at the beginning and end of the Baf A1 treatment period) [72]. Since the 
kinetics of LC3-II synthesis and degradation have not been established in our model, the level of 
autophagy in HL-1 cells was determined by comparing the level of cumulative LC3-II between 
samples.   
 The role of autophagy was assessed by inhibiting the initiation step of autophagy 
with 3-methyaldenine (3-MA), a Class III PI3-K inhibitor. The dose-response study of 3-MA 
(dissolved in sterile water) indicated that the administration of 10 mM in cardiac cultures for 2 
hours induced a decrease in the level of LC3-II as assessed by Western blotting. The 3-MA-
mediated inhibition of autophagy resulted in little cytotoxicity as measured by flow cytometric  
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Figure 5: Effect of bafilomycin A1 on autophagy and viability of HL-1 cardiac cells.  
A. Profile of LC3 processing in HL-1 cells incubated with increasing concentrations of 
bafilomycin A1 (Baf A1, 0-200 nM), with DMSO (vehicle) or with the lysosomal inhibitors 
cocktail (LIC, 100 nM Baf A1, 5 µg/mL E64D,  5 µg/mL pepstatin A methyl ester) for 2 
hours assessed by Western blotting. β-tubulin was used as a loading control. B. Flow 
cytometric analysis of HL-1 cells incubated for 2 hours with Baf A1 (25 nM) or LIC and 
labeled with AnnexinV-FITC and propidium iodide (PI). Control samples include HL-1 cells 
that were untreated (Control), treated with vehicle alone (DMSO: 0.025% or 0.2%, for Baf A1 
or LIC, respectively) or treated with 5 µM of cycloheximide (CHX) for 24 hours. The 
percentages of dead cells (Annexin V+/--PI+) and early apoptotic cells (Annexin V+-PI-) were 
expressed as mean ± SEM from two independent experiments and represented graphically. 
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Figure 6: Effect of 3-methyladenine on autophagy and viability of HL-1 cardiac cells. A. 
Profile of LC3 processing in HL-1 cells incubated for 2 hours with increasing concentrations 
of 3-methyladenine (3-MA) as analyzed by Western blotting. β-tubulin was used as a loading 
control. B. Flow cytometry analysis of HL-1 cells that were untreated (Control) or treated 
with 3-MA (10 mM) for 2 hours and labeled with AnnexinV-FITC and propidium iodide (PI). 
The percentages of dead cells (Annexin V+/--PI+) and early apoptotic cells (Annexin V+-PI-) 
were expressed as mean ± SEM from five independent experiments and represented 
graphically. *p<0.01 (vs. Control) by One-Way ANOVA. 
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analysis of Annexin V-PI double stained cells (Figure 6). Based on these results, the inhibition of 
autophagy was achieved by incubating HL-1 cells with 10 mM 3-MA for a maximal period of 2 
hours. 
  
2.7. Measurement of ATP Levels 
ATP levels were measured by a biochemiluminescent-based assay that relies on the 
property of the firefly luciferase to oxidize the substrate D-luciferin in an ATP-dependent 
process generating chemiluninescence. The light intensity is a direct measure of ATP 
concentration. This assay was performed using the ATPlite assay kit, according to the 
instructions of the manufacturer. Briefly, HL-1 cells were plated (in triplicate for each treatment 
group) in a black 96-well plate with a density of 15,000 cells/100 µL per well. Cells were 
allowed to attach overnight and subsequently subjected to the indicated treatment. The release of 
intracellular ATP was achieved by adding 50 µL of Mammalian Lysis Buffer to the cells. Cells 
were shaken at 700 rpm for 5 min and 50 µL of a solution containing D-luciferin (substrate) and 
luciferase (enzyme) was added to the cells. Cell lysates were shaken at 700 rpm for 5 min and 
incubated for 10 min in the dark. The luminescence was analyzed after a 1-sec delay with a 10-
msec integration on an Infinite M200 microplate reader (Tecan Group Ltd., Switzerland). A 
standard curve was generated from known concentrations of ATP (0-24 µM) and used to 
calculate the concentration of ATP in each sample. Luminescence increased linearly with the 
negative log of the ATP concentration in the samples over the range of concentrations measured. 
The ATP level (pmoles of ATP in 15,000 cells) of each sample was normalized to the ATP level 
measured in control cells before their exposure to hypoxia (2.2 nmoles of ATP/15,000 cells) and 
graphically represented as mean ± SEM in relation to control from at least three experiments. To 
  
28
determine whether compounds present in the ischemia buffer or standard cell culture media 
interfered with reagents of the ATP assay kit, the following control experiment was performed. 
HL-1 cardiac cells were subjected to 2 hours of hypoxia (0.5% O2) alone or followed by 2 hours 
of reoxygenation (H2/R2). Control groups included HL-1 cells incubated under normal 
conditions of growth for the periods of time that corresponded to those of the experimental 
groups. At the end of the treatment period, cells were lysed and 10 µM of purified ATP was 
added to the cell lysates. Following the addition of the substrate solution, the luminescence was 
read. As documented in Figure 7, following hypoxia alone and H/R, the ATP content of HL-1 
cells was significantly decreased in comparison to healthy cells. The addition of extracellular 
ATP resulted in an enhancement of the luminescence measured in the samples (control and 
treatment) that was proportional to the amount of ATP added. These data suggest that the low 
ATP contents measured in hypoxic cardiac cultures and HL-1 cells exposed to H/R did not result 
from a technical artifact. 
 
2.8. Trypan Blue Exclusion Assay 
Following the indicated treatment, cardiac cultures were washed with PBS, incubated for 
2 min in 0.25 mg/mL trypsin in versene (0.2 g/L EDTA•4Na in PBS) and then neutralized by the 
addition of FBS. Cells were centrifuged (1,500 rpm for 2 min). The supernatant was aspirated 
and the cells were resuspended in a suitable volume of PBS (0.5 mL). Following addition of an 
equal volume of 0.4% Trypan blue, the cells (adherent and floating) were counted in a 
hemocytometer. The number of dead cells with disrupted membranes (blue cells) in a total of 
200 cells was counted in duplicate, for each dish of plated cells. The level of cell death 
(percentage of blue cells/total cells) of each treatment group was normalized to the basal level of  
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Figure 7: Effect of extracellular ATP on ATP levels measured in HL-1 cardiac cells 
exposed to hypoxia-reoxygenation. HL-1 cells were untreated (Control) or exposed to 2 
hours of hypoxia (0.5% O2) alone (H2) or followed by 2 hours of reoxygenation (H2/R2). 
ATP levels were measured in absence (untreated) or presence of 10 µM ATP and 
represented graphically as mean ± SEM from three independent experiments. **p<0.0001 
(vs. Control) and #p<0.0001 (vs. untreated) by One-Way ANOVA.    
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cell death measured under control conditions (3-5%) and was graphically represented as the 
mean ± SEM in relation to controls from at least three experiments. 
 
2.9. Measurement of Phosphatidylserine Exposure by Annexin V Binding  
The adherent cells were rinsed twice with PBS before harvesting by incubating them for 
2 min in 0.25 mg/mL trypsin in versene. The trypsin was neutralized through addition of FBS. 
Floating and adherent cells were washed twice with ice cold PBS and resuspended in 1X Binding 
buffer to a final concentration of 1 x 106 cells/mL. Cells (1 x 105) were incubated for 15 minutes 
at room temperature in the dark with 5 µL FITC-Annexin V and 5 µL Propidium Iodide (PI) 
according to the manufacturer’s instructions. At the end of the incubation period, 1X Binding 
buffer (400 µL) was added to the cells. HL-1 cells were analyzed by flow cytometry. Control 
samples included unstained cells, cells stained with FITC-Annexin V alone and cells stained with 
PI alone. For each sample, 2 x 104 cells were analyzed on a LSR II flow cytometer (Becton 
Dickinson). Annexin V-FITC and PI signals were excited using a 488-nm laser light and 
emissions were captured using bandpass filters set at 530 ± 30 and 613 ± 20 nm, respectively. 
Cell Quest Acquisition and Analysis software (BD Bioscience, CA) was used to acquire and 
quantify fluorescence signal intensities and draw bivariate dot-density plots. Numbers in the 
lower left (LL), the upper right (UR), the lower right (LR) and upper left (UL) quadrants  denote 
percentages of viable cells (Annexin V-/PI-), necrotic or late apoptotic cells (Annexin V+/PI+), 
early apoptotic cells (Annexin V+/PI-), and non viable cells (Annexin V-/PI+), respectively. The 
percentages of dead cells (UL+UR - Annexin V+/-/PI+) and early apoptotic cells (LR - Annexin 
V+/PI-) relative to control levels were expressed as mean ± SEM from at least three independent 
experiments and represented graphically.  
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2.10. Statistical Analysis  
For all of the outcomes collected in this project, descriptive statistics for each 
experimental group were performed. These statistics included means, medians, standard 
deviations, ranges and confidence intervals. The data were expressed as means ± SEMs and 
represented graphically to provide visualization of the group trends. All experiments were 
repeated at least three times. Statistical analysis between two groups was performed by Student’s 
t test. In most of the following studies involving more than two groups, single-factor one way 
analysis of variance (ANOVA) was performed for each group of treatments. When a significant 
experimental effect was detected (p<0.05), pairwise comparisons of the different levels of the 
factor were performed using the Bonferonni post-test. The interaction between various factors 
was analyzed by the two factor ANOVAs. When a significant interaction was detected, further 
analyses were done to assess the effect of one factor within each level of the other factor and vice 
versa.  
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CHAPTER 3 – RESULTS 
 
3.1. Validation of the In Vitro Model of Cardiac Ischemia-Reperfusion Injury 
For our in vitro model of I/R injury (hypoxia-reoxygenation, H/R), the murine atrial-
derived HL-1 cell line was used as a cellular model because of the multiple advantages it offers. 
Primary cultures of isolated cardiac myocytes can be contaminated with other cell types 
(endothelial cells, fibroblasts and leucocytes) and can undergo spontaneous deterioration. In 
contrast, HL-1 cells constitute a homogeneous cell population that can continuously divide while 
retaining many features of mature cardiomyocytes [68]. These characteristics ensure not only 
that the changes in a process can be attributed to a single cell type, but a greater reproducibility 
of the results as well. The HL-1 cell line represents an excellent tool for studying normal and 
pathophysiological cardiomyocyte functions. [73].  
In our model, ischemia (hereafter referred to as hypoxia) was induced by replacing the 
standard medium with an “ischemia buffer” and placing HL-1 cardiac cultures in a hypoxic 
atmosphere. The “ischemia buffer” was formulated to mimic the extracellular environment and 
the reduced energy state that cardiomyocytes are exposed to during ischemia in vivo. The 
“ischemia buffer” contains 2-deoxyglucose, a glucose analogue unable to undergo glycolysis, 
which ultimately inhibits cellular metabolism. In addition, the buffer contains a high 
concentration of potassium (hyperkalemia) and has an acidic pH (6.8). The use of this model has 
been successful in identifying key biochemical and cellular events involved in triggering cardiac 
cell death following H/R [40,57,58]. In contrast to other studies carried out in the model of 
simulated I/R injury, our model is unique in the sense that two different concentrations of O2 – 
0.5% and 2.0% were used to achieve different degrees of ischemia. This approach allowed us to 
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get closer to the situation encountered in patients suffering from myocardial infarction. In these 
patients, although the occlusion of the coronary artery induces nearly complete ischemia in the 
risk area with subsequent irreversible damage, the peri-infarct penumbra of the myocardium 
maintains a low level of oxygen by diffusion from adjacent areas. Finally, the “reperfusion” 
(hereafter referred to as reoxygenation) was achieved by restoring the normal culture conditions.  
 
3.1.1. The bioenergetic status of HL-1 cells during hypoxia-reoxygenation 
The primary focus was to determine whether the experimental conditions used to mimic 
ischemia in cultured HL-1 cardiac cells triggered the same metabolic changes encountered in the 
ischemic cardiomyocytes in vivo. To do so, HL-1 cardiac cultures were incubated in the ischemia 
buffer in presence of 0.5% or 2.0% O2 for increasing periods of time (30, 60 and 120 minutes) 
and the ATP levels were measured at the end of each hypoxic period. As shown in Figure 8A, 
the ATP content of HL-1 cells dropped significantly following 30 minutes of hypoxic exposure 
to reach 15% of control levels by 2 hours of hypoxia induced with both 0.5% and 2.0% O2. 
Interestingly, the degree of hypoxia had a differential effect on the rate of ATP depletion during 
the first 30 minutes. HL-1 cells exposed to 2.0% O2 maintained a slightly, though significantly, 
higher ATP content than cells exposed to 0.5% O2, ATP reached 32% and 24% of control levels, 
respectively (p<0.001 by two-way ANOVA). These results indicate that the experimental 
approach used to simulate ischemia in HL-1 cardiac cultures induced a dramatic ATP depletion, 
a pathological hallmark of myocardial infarction. To determine whether the restoration of normal 
conditions promoted the replenishment of intracellular ATP stores, the ATP level was measured 
in HL-1 cells subjected to 2 hours of hypoxia (0.5% or 2.0% O2) followed by 1, 2 and 4 hours of 
reoxygenation. The results shown in Figure 8B indicate that reoxygenation elicited a progressive 
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restoration of ATP production in myocytes. However, the ATP levels remained remarkably 
lower than control at all time points during reoxygenation. Importantly, the degree of hypoxia 
significantly influenced the rate of ATP replenishment elicited by reoxygenation. Following 4 
hours of reoxygenation, HL-1 cells previously exposed to 2.0% O2 had a higher ATP content 
than cells pre-exposed to 0.5% O2. The ATP levels reached 30% and 23% of control, 
respectively. These data indicate that reoxygenation promoted a partial re-energization of 
hypoxic cardiomyocytes. Other events triggered by either hypoxia or reoxygenation such as 
oxidative stress and mitochondrial damage may prevent the complete recovery of the myocyte 
bioenergetic state.  
To further assess the changes in the bioenergetic status of HL-1 cells induced by hypoxia 
and H/R, the activation of AMPK was used as an alternative indicator. AMPK senses the 
changes of the intracellular AMP/ATP ratio. In response to elevated AMP cellular content, 
AMPK is activated through phosphorylation of the catalytic α subunit at threonine 172 (Thr172) 
by the upstream AMPK kinases (AMPKKs). As a result, the utilization of ATP is reduced and 
ATP production is facilitated (e.g. by fatty acid oxidation) [74]. As shown in Figure 9A, the 
degree of AMPKα phosphorylation at Thr172 in HL-1 cells was significantly enhanced at all 
time points during hypoxia (0.5% or 2.0% O2) with respect to control conditions. These levels 
remained constant throughout the 2 hour-period in healthy HL-1 cells. In addition, the expression 
levels of AMPKα were apparently, but not significantly elevated at all time points during 
hypoxia (0.5% and 2.0% O2) compared to control cells. It is noteworthy that the band 
corresponding to AMPKα is slightly shifted up in the hypoxic samples, suggesting that AMPK is 
fully phosphorylated/activated during hypoxia. These results were consistent with the low 
energetic status of hypoxic cells.  
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A.
B.
Figure 8: The bioenergetic status of HL-1 cells exposed to hypoxia-reoxygenation. A. 
HL-1 cells were exposed to hypoxia (0.5% or 2.0% O2) for 30, 60 and 120 minutes. B. HL-1 
cells were exposed to 2 hours of hypoxia (0.5% or 2.0% O2) followed by 1, 2 and 4 hours of 
reoxygenation (H2/R1, H2/R2 and H2/R4). The levels of ATP were measured and expressed 
as percentages relative to controls. ATP levels were represented as mean ± SEM from three 
independent experiments. #p<0.005 (vs. H2/R1) by One-Way ANOVA. The comparison 
between the oxygen concentrations (0.5% and 2.0%) was performed by Two-Way ANOVA.  
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To test whether the partial recovery of ATP production occurring during reoxygenation was 
associated with a down-regulation of AMPKα activity, the levels of expression and activation of 
AMPKα were assessed in HL-1 cells subjected to 2 hours of hypoxia (0.5% or 2.0% O2) 
followed by 1, 2 and 4 hours of reoxygenation by Western blotting. The results shown in Figure 
9B indicate that reoxygenation induced a partial dephosphorylation of AMPKα in previously 
hypoxic HL-1 cells. The levels of phosphorylated AMPKα in HL-1 cells pre-exposed to 0.5% or 
2.0% O2 were significantly enhanced following 4 hours of reoxygenation in comparison to 
healthy cells (p<0.05 by one-way ANOVA). Although, the levels of AMPKα activation were 
also found to be significantly elevated following 2 hours of reoxygenation by Student’s t-Test. 
Importantly, reoxygenation had no effect on the abundance of AMPKα in myocytes, this level 
remained constant throughout the reoxygenation period in comparison to healthy cells. These 
results suggest that the partial recovery of ATP production in reoxygenating HL-1 cells was 
accompanied by a concomitant and incomplete dephosphorylation of AMPKα. Altogether, these 
data support the validity of our in vitro model of myocardial ischemia as it recapitulated the low 
energetic state of cardiomyocytes induced by ischemia and a partial recovery of ATP production 
during reperfusion.   
 
3.1.2. HL-1 cell viability following hypoxia-reoxygenation 
We then sought to establish the extent of cell injury elicited by both hypoxia and H/R. We 
have examined the level of cardiac cell death induced by 2 hours of hypoxia (0.5% or 2.0% O2). 
Cell viability was measured by assessing the ability of myocytes to exclude Trypan blue, a vital 
dye that penetrates dead cells through their damaged membrane. Hypoxia significantly increased 
cell death in comparison to control conditions (Figure 10A). Importantly, cells exposed to 0.5% 
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Figure 9: Time course of AMPKα expression and phosphorylation in HL-1 cells 
exposed to hypoxia-reoxygenation. A, B. HL-1 cells were exposed to hypoxia (0.5% or 
2.0% O2) for 30, 60 and 120 minutes. C, D. HL-1 cells were exposed to 2 hours of hypoxia 
(0.5% or 2.0% O2) followed by 1, 2 and 4 hours of reoxygenation (H2/R1, H2/R2 and 
H2/R4). Control cells were incubated under normal conditions for the same periods of time 
(C). The levels of expression and phosphorylation of AMPKα were assessed by Western 
botting. The levels of phosphorylated and total AMPKα were measured by densitometry 
analysis of the immunoreactive bands and normalized to actin. Results were graphically 
represented as mean ± SEM from four independent experiments. *p<0.001, #p<0.005, 
+p<0.05 (vs. C) by One-Way ANOVA.  
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O2 were more susceptible as the number of dead cells reached 358% of control (vs. 321% of 
controls in the case of 2.0% O2, p<0.0001 by one-way ANOVA). These results suggest that the 
degree of hypoxia dictates the extent of cardiac injury. Since the occurrence of apoptosis has also 
been reported in the ischemic myocardium, we have monitored the activation of apoptosis in HL-
1 cells exposed to 2 hours of hypoxia with 0.5% or 2.0% O2. The translocation of 
phosphatidylserine (PS) residues from the inner to the outer leaflet of the cell membrane is an 
early event of the apoptotic program and was therefore used as a marker of early apoptosis. Thus, 
HL-1 cells were stained with fluorescein-labeled Annexin V (a calcium-dependent phospholipid-
binding protein that exhibits a high binding affinity for accessible PS) and propidium iodide (PI, 
a fluorescent DNA intercalating dye that penetrates dead or damaged cells) and analyzed by flow 
cytometry. This technique is not suitable to discriminate between cells that are necrotic and late 
apoptotic. Indeed, during the late stage of apoptosis, apoptotic bodies are formed and are 
phagocytosed by macrophages. However, in cells in culture, the removal of apoptotic cells by 
phagocytes is not possible and thus these cells inevitably die by necrosis. In addition, Annexin V 
is able to insinuate through the disrupted membranes of necrotic cells, and bind to their internally 
located PS residues. Consistent with this, flow cytometric analysis of Annexin V-PI stained cells 
revealed three cell populations (i) viable cells (Annexin V- and PI-), (ii) early apoptotic cells 
(Annexin V+ and PI-) and (iii) dead cells (Annexin V+/- and PI+). Our results show that hypoxia 
induced a significant increase in cell death that was more pronounced with 0.5% than 2.0% O2; 
the percentages of dead cells reached 284% and 250% of control levels, respectively (p<0.0001 
by one-way ANOVA) (Figure 10B, C). These results were in agreement with the level of 
hypoxic cell death measured by Trypan blue staining. Importantly, the level of cells undergoing 
early apoptosis following hypoxia remained similar to controls. Altogether, these data indicate 
  
39
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
that the viability of HL-1 cells was significantly and differentially affected by the degree of 
hypoxia.   
Figure 10: Effect of hypoxia on HL-1 cell viability. HL-1 cells were incubated under 
normal conditions (Control) or exposed to hypoxia (H) with 0.5% or 2.0% O2 for 2 hours. A. 
Cell death was evaluated by Trypan blue staining. The percentages of dead cells (Trypan Blue 
positive/total cells) relative to controls were represented graphically as mean ± SEM from 
three independent experiments. **p<0.0001 (vs. 0.5% O2) by One-Way ANOVA. B, C. Flow 
cytometric analysis of HL-1 cells labeled with FITC-Annexin V and Propidium Iodide (PI). 
The percentages of dead cells (Annexin V+/--PI+) and early apoptotic cells (Annexin V+-PI-) 
relative to controls were expressed as mean ± SEM from three independent experiments and 
graphically represented. #p<0.001 (vs. 0.5% O2) by One-Way ANOVA. 
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that the viability of HL-1 cells was significantly and differentially affected by the degree of 
hypoxia. 
Next, we determined whether reoxygenation exacerbated or limited cardiac cell injury 
induced by hypoxia. HL-1 cells were exposed to 2 hours of hypoxia followed by increasing 
periods of reoxygenation (2 and 4 hours) and cell death was assessed by Trypan blue exclusion. 
The results indicate that the level of cell death remained elevated during the 4-hour period of 
reoxygenation compared to control conditions (Figure 11A). However, the number of cells 
accumulating the dye was significantly decreased after 4 hours of reoxygenation. In addition, 
myocytes exposed to 2.0% O2 were significantly less prone to death during the first 2 hours of 
reoxygenation than cells exposed to 0.5% O2. The apparent decrease in cardiac cell death 
observed during reoxygenation may be due to cells that have lysed and therefore not counted.  
We have assessed the occurrence of apoptosis in HL-1 cells subjected to 2 hours of 
hypoxia followed by 2, 4, 9 and 16 hours of reoxygenation by Annexin V-FITC and PI staining 
and flow cytometry. Following hypoxia, cell death was reduced by half following 2 hours of 
reoxygenation (Figure 11B). Importantly, cardiomyocyte death occurred to a similar extent 
during reoxygenation and normal conditions. In contrast, reoxygenation triggered the activation 
of the apoptotic program in hypoxic cardiomyocytes. Although the level of early apoptosis was 
elevated at all time points during reoxygenation in comparison to control conditions, the 
temporal profile of apoptosis activation differed depending on the degree of hypoxia. In the case 
of 0.5% O2, the percentage of early apoptotic myocytes increased to 143% of control during the 
first 2 hours of reoxygenation, peaked by 4 hours to reach 217% of control level, and 
progressively decreased thereafter to reach 161% of control level by 16 hours. In contrast, when 
hypoxia was induced with 2.0% O2, the level of early apoptotic cells increased to reach a peak by 
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Figure 11: Cardiac cell death following hypoxia-reoxygenation. A. HL-1 cells were 
exposed to 2 hours of hypoxia (0.5% or 2.0% O2) followed by 2 and 4 hours of 
reoxygenation (H2/Rs) and cell death was evaluated by Trypan blue exclusion. The 
percentages of dead cells relative to healthy controls were represented graphically as 
mean ± SEM from three independent experiments. +p<0.05 (vs. H2/R2) by One-Way 
ANOVA. B, C. Flow cytometric analysis of Annexin V and Propidium Iodide labeling of 
HL-1 cells that were healthy (Control) or subjected to 2 hours of hypoxia (0.5% or 2.0% 
O2) followed by 2, 4, 9 and 16 hours of reoxygenation (H2/Rs). The percentages of dead 
cells (Annexin V+/-/PI+) and early apoptotic cells (Annexin V+/PI-) relative to control 
levels were expressed as mean ± SEM from three independent experiments and 
represented graphically. **p<0.0001, *p<0.005 (vs. H2/R2); **p<0.0001, #p<0.01, 
*p<0.005, +p<0.05 (vs. H2/R4); +p<0.05 (vs. H2/R9) by One-Way ANOVA. 
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2 hours of rexoygenation (249% of control) and decreased to attain 180% of control level by 16 
hours of reoxygenation. These results indicate that reoxygenation triggered  
In summary, we have validated our model of myocardial ischemia as we have found that 
hypoxia triggered a drastic depletion of ATP in HL-1 cells, a hallmark of ischemia. This effect 
was accompanied by an increase in cell death that was more pronounced when cardiac cultures 
were exposed to 2 hours of hypoxia induced with 0.5% than with 2.0% O2. In turn, 
reoxygenation promoted a partial bioenergetic recovery of hypoxic HL-1 cells. This effect was 
accompanied by an activation of the apoptotic program. These data suggest that the low ATP 
levels present in reoxygenating myocytes were sufficient to trigger apoptosis. However, the 
status of biochemical markers of later stages of apoptosis have not been examined, therefore it is 
unknown whether these ATP levels would be sufficient for the completion of the apoptotic 
program.    
 
3.2. Modulation and Role of Autophagy during Hypoxia-Reoxygenation 
 
3.2.1. Autophagy in HL-1 cells exposed to hypoxia-reoxygenation 
As we have demonstrated that our system was a suitable model of myocardial I/R injury, 
the next objective of this project was to study autophagy. First, we have established the temporal 
profile of autophagy in HL-1 cardiomyocytes exposed to hypoxia induced with 0.5% or 2.0% O2. 
The induction of autophagy was monitored by assessing the intracellular level of LC3-II, the 
specific marker of the autophagosome, by western blotting. An increase in the intracellular level 
of LC3-II can result from two distinct phenomena, an up-regulation of the autophagic process or 
a blockade of its lysosomal degradation phase. Thus, to discriminate between these possibilities, 
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it was essential to block the lysosomal degradation of LC3-II, which, in turn, leads to a time-
dependent accumulation of LC3-II. This was achieved by incubating HL-1 cardiac cultures with 
25 nM Baf A1, an inhibitor of the autophagosome-lysosome fusion. The level of autophagy was 
estimated by comparing the LC3-II levels in the presence of Baf A1 (cumulative LC3-II) 
between the samples. As depicted in Figure 12, the hypoxic treatment had no effect on the level 
of LC3-I in HL-1 cells. In addition, the autophagic response of HL-1 cells was not altered 
following 1 hour of hypoxia induced with either 0.5% or 2.0% O2. However, a prolonged period 
of hypoxia (2 hours) induced a differential effect on autophagy, depending on the level of 
oxygen. HL-1 cells exposed to 0.5% O2 exhibited a lower level of autophagy as judged by the 
significant decrease in LC3-II accumulation when compared to healthy HL-1 cells (Figure 12A). 
In contrast, the level of autophagy in cardiac cultures exposed to a hypoxic atmosphere 
containing a higher concentration of oxygen (2.0% O2) remained similar to control cells (Figure 
12B). These results suggest that the degree of hypoxia is a determining factor in the autophagic 
response elicited in HL-1 cells. To determine how reoxygenation affected this outcome, we have 
assessed the level of autophagy in HL-1 cells exposed to 2 hours of hypoxia (0.5% or 2.0% O2) 
followed by 1, 2 and 4 hours of reoxygenation (H2/R1, H2/R2 and H2/R4). As previously 
described, the level of autophagy was assessed by comparing the levels of LC3-II measured in 
presence of 25 nM Baf A1 by western blotting, present in healthy myocytes and HL-1 cells 
exposed to H/R. The incubation period with Baf A1 was limited to 2 hours to prevent non-
specific effects mediated by the long-term blockade of autophagy. Thus, Baf A1 was present 
throughout (H2/R1, H2/R2) or during the last 2 hours of the reoxygenation period (H2/R4). In 
parallel, healthy cultures were incubated under normal conditions and subjected to the same Baf  
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Figure 12: Temporal profile of autophagy in hypoxic HL-1 cardiomyocytes. HL-1 cells 
were exposed to increasing periods of hypoxia (H) with A. 0.5% O2 or B. 2.0% O2. 
Bafilomycin A1 (25 nM) was absent (-) or present (+) during the hypoxic period. Cell lysates 
were analyzed by Western blotting for LC3. Actin was used as a loading control. Control 
samples (C) include HL-1 cells grown under normal conditions for the same time periods in 
the absence or presence of Baf A1. The ratio LC3-II/Actin were determined by densitometry 
analysis of the immunoreactive bands and represented graphically as mean ± SEM from five 
independent experiments. *p<0.01 (vs. C 120 min), #p<0.001 (vs. H 60 min) by One-Way 
ANOVA. 
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Figure 13: The modulation of autophagy during hypoxia-reoxygenation. HL-1 cells 
were exposed to 2 hours of hypoxia with 0.5% O2 (A) or 2.0% O2 (B) followed by 1, 2 
and 4 hours of reoxygenation (H2/Rs). Bafilomycin A1 (Baf A1, 25 nM) was absent (-) or 
present (+) throughout the reoxygenation period (H2/R1, H2/R2) or during the last 2 hours 
of reoxygenation (H2/R4). Cell lystaes were prepared and analyzed by Western blotting 
for LC3. Actin was used as a loading control. Control samples (C) include HL-1 cells 
grown under normal conditions for the same periods in the absence or presence of Baf A1. 
The ratio LC3-II/Actin were determined by densitometry analysis of the immunoreactive 
bands and represented graphically as mean ± SEM from three independent experiments. 
+p<0.05 (vs. C) by One-Way ANOVA. 
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A1 treatment for identical periods. Our results indicate that the levels of LC3-I in HL-1 cells 
were not altered by the reoxygenation process. In addition, cardiomyocytes exposed to H/R 
exhibited different temporal profiles of autophagy depending on the degree of hypoxia.  
Following 2 and 4 hours of reoxygenation, the cumulative levels of LC3-II in myocytes exposed 
to 0.5% O2 were significantly lower compared to healthy cells (Figure 13A). In contrast, the 
level of autophagy in HL-1 cells pre-exposed to hypoxic conditions of 2.0% O2 was similar to 
controls during the first 2 hours of reoxygenation but was significantly attenuated by 4 hours of 
reoxygenation compared to healthy cells (Figure 13B).  These results suggest that the process of 
autophagy was compromised in HL-1 cells during H/R with a timing that was oxygen-dependent.  
 
3.2.2. Mode of regulation of autophagy in HL-1 cells during hypoxia-reoxygenation  
We next sought to investigate the molecular mechanisms underlying the autophagic 
response elicited by H/R. Our previous results showed that hypoxia (2 hours), according to its 
degree, had a differential effect on the level of autophagy in HL-1 myocytes. The level of 
autophagy was either unchanged (2.0% O2) or partially inhibited (0.5% O2) compared to healthy 
cells (Figure 12). ATP is required for the successful completion of autophagy. Thus, it is likely 
that the low ATP content of hypoxic cells limited their autophagic response. To test this 
possibility, HL-1 cells were incubated in the ischemia buffer containing glucose instead of 2-
deoxyglucose (2-DG, an inhibitor of glycolysis) and exposed to 0.5% or 2.0% O2 for 60 and 120 
minutes. The bioenergetic status of cardiac cells was subsequently assessed by measuring ATP 
levels and analyzing the expression and phosphorylation profiles of AMPKα by Western 
blotting. As documented in Figure 14A, HL-1 cells exposed to 60 and 120 minutes of hypoxia in 
presence of glucose exhibited lower ATP contents in comparison to controls. Interestingly, the 
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decrease in ATP was dependent on the level of oxygen present during hypoxia. Indeed, the ATP 
levels of myocytes exposed to 0.5% and 2.0% O2 reached 40% and 50% of controls, respectively. 
However, these levels remained 2 to 3-fold higher than the levels of ATP of cells exposed to 
hypoxia in presence of 2-DG. These results suggest that the drastic ATP depletion induced by 
hypoxia was in part mediated by 2-DG and additional factors including oxygen may contribute to 
that effect. The levels of AMPKα phosphorylation in myocytes exposed to hypoxia in presence 
of glucose appeared to be slightly increased in comparison to healthy cells (Figure 14B). 
However, a statistical difference was observed only for myocytes exposed to 2 hours of hypoxia 
induced with 0.5% O2. HL-1 cells exposed to hypoxia in presence of 2-DG exhibited 
significantly elevated levels of phosphorylated AMPKα. The abundance of AMPK was not 
significantly affected by hypoxia. Next, we sought to determine whether the levels of ATP 
present in HL-1 cells exposed to hypoxia in presence of glucose could promote autophagy. We 
found that autophagy was significantly enhanced in cells exposed to 60 and 120 minutes of 
hypoxia (0.5% and 2.0% O2) in presence of glucose in comparison to cells that were healthy or 
subjected to hypoxia in presence of 2-DG (Figure 15). In addition, the level of autophagy was 
increased to a similar extent in cells exposed to 0.5% and 2.0% O2 in presence of glucose. These 
results confirm that energy is a limiting factor in the hypoxia-induced autophagic response of 
HL-1 myocytes. However, the attenuation of autophagy in hypoxic myocytes exposed to 0.5% 
O2 appeared to be oxygen-dependent. Our results previously showed that the reintroduction of 
glucose (i.e. restoration of standard culture medium) in hypoxic cardiac cultures during 
reoxygenation did not enhance autophagy. Thus, the modulation of autophagy in HL-1 cells 
during hypoxia and reoxygenation may involve distinct mechanisms.   
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Figure 14: The bioenergetic status of HL-1 cells exposed to hypoxia in presence of 
glucose. HL-1 cells were exposed to 60 or 120 minutes of hypoxia (0.5% and 2.0% O2) 
in presence of 20 mM Glucose (H+G) or 10 mM 2-deoxyglucose (H). Control cells were 
grown in normal conditions for identical periods of time (C). A. The ATP contents were 
measured and represented as mean ± SEM relative to healthy cells (% Control) of three 
independent experiments. **p<0.0001 (vs. H+G) by One-Way ANOVA and p<0.01 (vs. 
0.5% O2) by Two-Way ANOVA. B. AMPKα expression and phosphorylation profiles in 
HL-1 cells subjected to the aforementioned treatments were analyzed by Western 
blotting. The protein levels were normalized to actin (loading control). The results were 
graphically represented as mean ± SEM of three independent experiments. **p<0.0001, 
*p<0.001, #p<0.01 (vs. C), and **p<0.0001, *p<0.001, #p<0.01 (vs. H+G) by One-Way 
ANOVA.   
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Figure 15: Autophagy in HL-1 cells exposed to hypoxia in presence of glucose. HL-
1 cells were exposed to 60 or 120 minutes of hypoxia with 0.5% O2 (A) or 2.0% O2 (B) 
in presence of 20 mM Glucose (H+G) or 10 mM 2-deoxyglucose (H). Control cells were 
grown in normal conditions for the corresponding period of time (C). Baf A1 (25 nM) 
was absent (-) or present (+) throughout hypoxia. Autophagy was assessed by LC3 
Western blotting and actin was used as a loading control. The ratio LC3-II/Actin were 
determined by densitometry analysis of the immunoreactive bands and represented 
graphically as mean ± SEM from three independent experiments. **p<0.0001, *p<0.001, 
#p<0.01 (vs. C) by One-Way ANOVA.   
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 To further investigate the molecular mechanisms that control autophagy in HL-1 cells 
during H/R, we have explored the activation profiles of signaling pathways known to modulate 
this process (Figure 3). Under conditions of nutrient and energy depletion, autophagy is 
stimulated through inactivation of mTOR, a negative modulator of autophagy. mTOR inhibition 
can result from (i) the repression of the PI3-K/Akt pathway or from (ii) the activation of AMPK 
in response to low ATP levels. In addition, autophagy was shown to be activated by the Raf-1-
MEK1/2-ERK1/2 signaling cascade in response to amino acid depletion [32]. Thus, we have first 
examined the expression and phosphorylation (indicative of kinase activity) profiles of Akt, 
mTOR and ERK1/2 in healthy cells and HL-1 cells exposed to 30, 60 and 120 minutes of 
hypoxia (0.5% and 2.0% O2) by Western blotting (Figures 16a and 16b). Under normal 
conditions, the levels of expression and activation of Akt, ERK1/2 and mTOR remained constant 
throughout the 2-hour period. In contrast, hypoxia, whether induced with 0.5% or 2.0% O2, 
severely impaired the activation of Akt, ERK1/2 and mTOR in HL-1 cells. Interestingly, the 
kinetics of deactivation of these kinases differed markedly. The phosphorylation of ERK1/2 was 
dramatically reduced after 30 minutes and almost completely disappeared after 60 and 120 
minutes of hypoxia. The phosphorylation of mTOR at Ser2448, which was shown to correlate 
with the activation by growth factors [75], progressively decreased to reach 53%, 28% and 20% 
of control levels after 30, 60 and 120 minutes of hypoxia, respectively. In contrast, the 
phosphorylative activation of Akt declined at a slower rate as the level of Ser473-phosphorylated 
Akt reached 62% of control levels by 30 minutes of hypoxia. This level was sustained during the 
first hour of hypoxia and decreased to be barely detectable after 120 minutes of hypoxia. These 
results suggest that the deactivation of ERK1/2 was an early event during hypoxia and was 
followed by the consecutive dephosphorylation of mTOR and Akt. Importantly, the abundance 
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of ERK1/2, Akt and mTOR in HL-1 cells exposed to 2.0% O2 remained unchanged in 
comparison to healthy cells. However, hypoxia (0.5% O2) had a significant effect on the total 
expression levels of mTOR and Akt. While the expression level of mTOR was significantly 
elevated at all time points during hypoxia, Akt expression was enhanced by 60 minutes of 
hypoxia (0.5% O2) only. As described earlier, hypoxia induced a dramatic activation of the pro-
autophagic kinase, AMPKα without affecting its overall expression levels. Finally, we have 
established the expression profile of Beclin 1, which is involved, along with the class III PI3-K, 
in the autophagosome formation. The abundance of Beclin 1 in HL-1 cells was unaffected by 
hypoxia. Altogether, these results indicate that hypoxia significantly influenced the activation 
status of modulators of autophagy. While the inactivation of the Akt/mTOR pathway and the 
activation of AMPKα are consistent with a stimulation of autophagy, the inactivation of ERK1/2 
exerts an inhibitory action on autophagy. However, our previous results indicate that autophagy 
not only was not enhanced in hypoxic myocytes but also was partially repressed after 2 hours of 
hypoxia (0.5% O2). These results suggest the existence of a mechanism that may act in parallel to 
thwart the action of mTOR, thereby limiting the occurrence of autophagy. Alternatively, hypoxia 
may lead to a dysregulation of these pathways, presumably caused by the shortage in ATP.  
Next, we sought to determine the effect of reoxygenation on the hypoxia-mediated 
inactivation of Akt, ERK1/2 and mTOR. To this end, HL-1 cardiac cultures were subjected to 2 
hours of hypoxia (0.5% or 2.0% O2) followed by 1, 2 and 4 hours of reoxygenation. The 
temporal profiles of expression and phosphorylation/activation of Akt, ERK1/2, mTOR and 
Beclin 1 during H/R were analyzed by western blotting. As shown in Figure 17a and 17b, the 
levels of expression of Akt, ERK1/2, mTOR and Beclin 1 in HL-1 cells were similar to controls 
throughout the reoxygenation period. However, H/R induced a reactivation of Akt, ERK1/2 and   
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Figure 16a: Effect of hypoxia on modulators of autophagy. HL-1 cells were exposed to 
increasing periods of hypoxia (H) with 0.5% (left panel) or 2.0% (right panel) O2. The 
temporal profiles of expression and activation of modulators of autophagy (Akt, ERK1/2, 
mTOR and Beclin 1) were analyzed by immunoblotting. Actin was used as a loading 
control in all Western blots. Control cells were grown in normal conditions for periods of 
time corresponding to the treatment groups (C). Blots shown are representative of at least 
three independent experiments. The quantifications are shown in Figure 16b. 
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Figure 16b: Effect of hypoxia on modulators of autophagy. Quantifications of Akt, ERK1/2, 
mTOR and Beclin 1 expression and activation levels in HL-1 cells exposed to increasing periods 
of hypoxia (H) with 0.5% (left panel) or 2.0% (right panel) O2. The levels of expression of Akt, 
ERK1/2, mTOR and Beclin 1 were determined in relation to actin. The levels of phosphorylated 
Akt, ERK1/2 and mTOR were determined in relation to both, actin and the total protein level. The 
ratio were determined by densitometry analysis of the immunoreactive bands and represented 
graphically as mean ± SEM from at least three independent experiments. **p<0.0001, *p<0.001, 
#p<0.01, +p<0.05 (vs. C) by One-Way ANOVA. 
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mTOR in HL-1 cells. Akt phosporylation at Ser473 was significantly enhanced after 1 and 2 
hours of reoxygenation and declined to reach control levels by 4 hours of reoxygenation. In 
contrast, ERK1/2 exhibited distinct kinetics of reactivation. In comparison to healthy controls, 
ERK1/2 phosphorylation was significantly increased by 1 hour of reoxygenation and 
progressively declined to reach levels significantly lower than controls after 4 hours of 
reoxygenation. Interestingly, HL-1 cells exposed to H/R exhibited, to some extent, the same 
profile of mTOR phosphorylation as healthy cells. Myocytes exposed to 0.5% or 2.0% O2 
displayed similar profiles of phosphorylation of Akt, ERK1/2 and mTOR. In addition, we have 
previously shown that AMPKα phosphorylation was enhanced in HL-1cells following 4 hours of 
reoxygenation compared to healthy cells and that the protein levels were not affected by H/R. 
While the status of activation of Akt and mTOR might maintain basal levels of autophagy in HL-
1 cells exposed to H/R, the concomitant activation of AMPKα and inactivation of ERK1/2 were 
consistent with an enhanced autophagic activity. However, we observed that autophagy was 
repressed in HL-1 cells following 4 hours of reoxygenation. This effect may result from other 
cellular events triggered by H/R.   
 
3.2.3. The role of autophagy during cardiac hypoxia-reoxygenation 
To investigate whether autophagy is protective or detrimental to cardiac cells during 
hypoxia, we have employed a pharmacological approach to block autophagy at its initiation 
level. The class III PI3-K is involved in the sequestration step of autophagy and 3-methyladenine 
(3-MA) is commonly used to inhibit its activity [55]. Thus, HL-1 cells were exposed to 2 hours 
of hypoxia (0.5% or 2.0% O2) in presence or absence of 10 mM 3-MA. To verify the effect on 
the autophagic response, HL-1 cells were co-incubated with 25 nM Baf A1 and the LC3-II levels  
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Figure 17a: Effect of hypoxia-reoxygenation on modulators of autophagy. HL-1 cells 
were exposed to 2 hours of hypoxia with 0.5% (left panel) or 2.0% (right panel) O2 
followed by 1, 2 and 4 hours of reoxygenation (H2/Rs). The temporal profiles of 
expression and activation of Akt, ERK1/2, mTOR and Beclin 1 were analyzed by 
Western blotting. Actin was used as a loading control. Control cells were grown in 
normal conditions for the corresponding period of time (C). Results shown are 
representative of at least three independent experiments. The quantifications are shown in 
Figure 17b. 
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Figure 17b: Effect of hypoxia-reoxygenation on modulators of autophagy. Quantifications 
of Akt, ERK1/2, mTOR and Beclin 1 expression and activation levels in HL-1 cells exposed to 
2 hours of hypoxia with 0.5% (left panel) or 2.0% (right panel) O2 followed by 1, 2 and 4 hours 
of reoxygenation (H2/Rs). The levels of expression of Akt, ERK1/2, mTOR and Beclin 1 were 
determined in relation to actin. The levels of phosphorylated Akt, ERK1/2 and mTOR were 
determined in relation to both, actin and the total protein level. Ratio were determined by 
densitometry analysis of the immunoreactive bands and represented graphically as mean ± SEM 
from at least three independent experiments. **p<0.0001, *p<0.001, #p<0.01, +p<0.05 in 
comparison to the corresponding control (C) by One-Way ANOVA. 
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were assessed by western blot analysis. 3-MA reduced autophagy in healthy and hypoxic cells as 
judged by the dramatic decrease in LC3-II cumulative levels (Figure 18). This result indicated 
that 3-MA treatment efficiently inhibited autophagy in hypoxic cardiac cultures.   
To investigate the association of autophagy with cardiac cell death during hypoxia, HL-1 
cells were exposed to 2 hours of hypoxia (0.5% or 2.0% O2) in presence of 10 mM 3-MA and 
cell death was assessed by both Trypan blue exclusion and flow cytomteric analysis of Annexin 
V-PI stained myocytes. Under normal conditions, 3-MA slightly increased the basal level of cell 
death. The presence of 3-MA during the hypoxic period significantly enhanced hypoxia-
mediated cell death. The levels of dead (Trypan blue positive) cells exposed to 0.5 % and 2.0% 
O2 increased by 1.7- and 1.5-fold, respectively (Figure 19A). The same effect of 3-MA on cell 
death following hypoxia was observed by flow cytometric analysis, but to a lesser extent (Figure 
19B). The inhibition of autophagy did not affect the level of hypoxic cells undergoing apoptosis. 
These results suggest that autophagy promotes the survival of HL-1 cardiomyocytes during 
hypoxia. This finding was further confirmed by establishing the association between autophagy 
stimulation and hypoxia-induced cell death. Our previous results indicated that the substitution 
of glucose for 2-DG in the ischemia buffer caused an up-regulation of autophagy in HL-1 cells 
exposed to hypoxia (0.5% and 2.0% O2). Thus, we sought to determine whether this effect 
protected cardiac cells against the injurious effects of hypoxia. As shown in Figure 20, the 
presence of glucose during 2 hours of hypoxia induced a significant decrease in the percentage of 
Trypan blue positive cardiomyocytes. Interestingly, the cardioprotection afforded by glucose was 
slightly greater for hypoxic myocytes exposed to 0.5% O2 than 2.0% O2 as the number of dead 
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Figure 18: Effect of 3-methyladenine on autophagy in hypoxic cardiomyocytes. HL-1 
cells were exposed to 2 hours of hypoxia (H) with A. 0.5% O2 or B. 2.0% O2 and treated 
with 10 nM 3-MA (H + 3-MA). Baf A1 (25 nM) was absent (-) or present (+) throughout 
hypoxia. Control samples include HL-1 cells incubated under normal conditions (Control) 
and subjected to the same drug treatments. Actin was used as a loading control. Results 
are representative of two independent experiments. 
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Figure 19: Effect of 3-methyladenine on hypoxia-induced cardiac cell death. HL-1 
cells were exposed to 2 hours of hypoxia (H2) with 0.5% or 2.0% O2 in presence of 10 
mM 3-MA. A. Cell death was assessed by Trypan blue exclusion. The percentages of 
cell death in relation to controls (healthy cells) were represented graphically as mean ± 
SEM from three independent experiments. **p<0.0001 (vs. Hypoxic alone) by One-Way 
ANOVA, p<0.0001 (vs. 0.5% O2) by Two-Way ANOVA. B, C. Flow cytometric 
analysis of AnnexinV-PI stained cells. The percentages of dead cells (Annexin V+/--PI+) 
and early apoptotic cells (Annexin V+-PI-) relative to control levels expressed as mean ± 
SEM from three independent experiments and represented graphically. **p<0.0001, 
#p<0.001 (vs. Hypoxia alone) by One-Way ANOVA and p<0.01 (vs. 0.5% O2) by Two-
Way ANOVA.      
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Figure 20: Cardiac cell death following hypoxia induced in presence of glucose. 
HL-1 cells were exposed to 2 hours of hypoxia with 0.5% or 2.0% O2 in presence of 10 
mM 2-deoxyglucose (hypoxia alone) or 20 mM glucose (hypoxia + glucose). A. 
Necrotic cell death was assessed by Trypan blue exclusion. The percentages of cell 
death in relation to controls (healthy cells) were represented graphically as mean ± SEM 
from three independent experiments. **p<0.0001 (vs. hypoxia alone) by One-Way 
ANOVA, **p<0.0001 and #p<0.001 (vs. 0.5% O2) by Two-Way ANOVA. B, C. Flow 
cytometric analysis of AnnexinV-PI stained cells. The percentages of dead cells 
(UL+UR) and early apoptotic cells relative to control levels were represented 
graphically and expressed as mean ± SEM from three independent experiments. 
**p<0.0001, +p<0.01 *p<0.05 (vs. hypoxia alone) by One-Way ANOVA and **p<0.0001 
and #p<0.001 (vs. 0.5% O2) by Two-Way ANOVA. 
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cells reached 120% and 160% of controls, respectively (p<0.001 by two-way ANOVA). Similar 
results were obtained by flow cytometric analysis of Annexin-V/PI stained hypoxic cells (Figure 
20B, C). In addition, the reduction in cell death was accompanied by a concomitant increase in 
early apoptosis. Indeed, the presence of glucose during hypoxia resulted in a significant increase 
in the percentage of early apoptotic cells, which reached 118% and 251% of controls when 
hypoxia was induced with 0.5% and 2.0% O2, respectively (p<0.001 by two way ANOVA). 
These results suggest that the events triggered by glucose during hypoxia are oxygen-dependent. 
These findings further evidenced a cardioprotective role of autophagy during hypoxia. 
To define the role played by autophagy during reoxygenation, HL-1 cells were exposed 
to 2 hours of hypoxia (0.5% or 2.0% O2) followed by 2 and 4 hours of reoxygenation. Autophagy 
was inhibited during reoxygenation only, as 10 mM 3-MA was present throughout the 
reoxygenation period (H2/R2) or during the last 2 hours of reoxygenation (H2/R4). The 
successful inhibition of autophagy was verified by examining the levels of LC3-II in presence of 
25 nM Baf A1 in HL-1 cells exposed to H/R by Western blotting. As shown in Figure 21, 3-MA 
significantly reduced the levels of accumulation of LC3-II in both, healthy cells and myocytes 
exposed to H/R. To determine whether the inhibition of autophagy exacerbates or reduces cell 
death following H/R, cell death was measured in HL-1 cells exposed to H2/R2 and H2/R4. 3-
MA was present throughout reoxygenation (H2/R2) or added during the last two hours of 
reoxygenation (H2/R4). As shown in Figure 22A, 3-MA treatment significantly increased the 
percentage of cells accumulating Trypan blue during the 4-hour period of reoxygenation. In 
agreement with this, the level of dead cells (Annexin V+/--PI+) was significantly increased when 
autophagy was inhibited during the reoxygenation period as analyzed by flow cytomtery (Figure 
22B). These results indicate that 3-MA exacerbated cardiac cell death during reoxygenation. The 
  
62
findings concerning apoptosis were more complicated. Interestingly, 3-MA had opposite effects 
on early apoptosis depending on the degree of hypoxia. When hypoxia was induced with 0.5% 
O2, 3-MA increased the number of cells undergoing early apoptosis during the last two hours of 
reoxygenation (H2/R4). Conversely, the inhibition of autophagy during reoxygenation attenuated 
the level of early apoptosis in cardiac cultures pre-exposed to 2.0% O2. One possible explanation 
for these results is that 3-MA may accelerate the apoptotic program in HL-1 cells. In the case of 
0.5% O2, 3-MA enhanced the level of cells undergoing early apoptosis. In contrast to severe 
hypoxia, cells that have been previously exposed to hypoxic conditions of 2.0% O2 exhibited 
higher level of early apoptosis following 2 hours of reoxygenation and it is likely that 3-MA 
induced a rapid progression from early to late apoptosis, resulting in a decrease in early apoptotic 
cells. This possibility can be tested by evaluating the levels of late apoptosis. Nevertheless, these 
data indicated that 3-MA enhanced both necrosis and early apoptosis during reoxygenation and 
provided evidence that despite its low level, autophagy plays a protective role during H/R.    
 
In summary, we have shown that hypoxia (2 hours), depending on its degree, either 
partially repressed autophagy in the case of 0.5% O2 or did not affect this process in HL-1 cells 
exposed to 2.0% O2. As we explored the molecular mechanisms underlying the autophagic 
response elicited by H/R, we demonstrated that energy limited autophagy in hypoxic cells and 
highlighted a disconnect between autophagy and the activation status of its key modulators. 
Indeed, the inhibition of mTOR mediated by AMPK and/or Akt did not lead to a stimulation of 
autophagy in hypoxic cardiomyocytes. In addition, the process of autophagy was significantly 
impaired in reoxygenating HL-1 cells with a timing that was oxygen-dependent. Reoxygenation 
induced a renormalization of the activation levels of Akt and mTOR suggesting that these 
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Figure 21: Effect of 3-methyladenine on autophagy in cardiomyocytes exposed to 
hypoxia-reoxygenation. HL-1 cells were exposed to 2 hours of hypoxia with A. 0.5% 
O2 or B. 2.0% O2 followed by 2 or 4 hours of reoxygenation. 3-MA (10 mM) was absent 
(H2/R2, H2/R4), present either throughout reoxygenation (H2/(R2 + 3-MA)) or during 
the last two hours of reoxygenation (H2/(R4 + 3-MA)). Baf A1 (25 nM) was absent (-) 
or present (+) throughout reoxygenation (H2/R2) or the last two hours of reoxygenation 
(H2/R4). Control samples include HL-1 cells incubated under normal conditions and 
subjected to the same drug treatments (Control, 3-MA). Autophagy was assessed by 
LC3 Western blotting and actin was used as a loading control. Results are representative 
of two independent experiments. 
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Figure 22: Effect of autophagy inhibition on hypoxia-reoxygenation-mediated HL-
1 cell death. HL-1 cells were exposed to 2 hours of hypoxia (0.5% or 2.0% O2) 
followed by 2 and 4 hours of reoxygenation (H2/Rs). 3-MA (10 mM) was present 
throughout the rexoygenation period (H2/R2) or during the last 2 hours of reoxygenation 
(H2/R4). A. Cell death was assessed by Trypan blue exclusion. The percentages of cell 
death in relation to controls were represented graphically as mean ± SEM from three 
independent experiments. **p<0.0001 (vs. H/R alone by One-Way ANOVA and p<0.01 
in comparison to Hypoxia (0.5% O2) by Two-Way ANOVA. B, C. Flow cytometric 
analysis of AnnexinV-PI stained cells. The percentages of dead cells (Annexin V+/-/PI-) 
and early apoptotic cells (Annexin V+/PI-) relative to control levels are expressed as 
mean ± SEM from three independent experiments and represented graphically. 
**p<0.0001 (vs. H/R alone) by One-Way ANOVA and p<0.0001 in comparison to 
Hypoxia (0.5% O2) by Two-Way ANOVA. 
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pathways may not be responsible for the repression of autophagic activity. In contrast the 
dephosphorylation of ERK1/2 and enhanced activation of AMPKα failed to increase autophagy 
during reoxygenation, suggesting the existence of other cellular events that limit autophagy. 
Finally, we have shown that autophagy serves as a protective mechanism during both hypoxia 
and reoxygenation. The stimulation of autophagy mediated by glucose and the inhibition of 
autophagy mediated by 3-MA, attenuated and enhanced cell death induced by hypoxia, 
respectively. The presence of 3-MA in reoxygenated cardiomyocytes exacerbated cell death 
following H/R.  
 
3.3. Effect of Sildenafil in HL-1 Cardiomyocytes Exposed to Hypoxia-Reoxygenation 
  
3.3.1. Cardioprotective effect of sildenafil during hypoxia-reoxygenation 
Sildenafil citrate (SNF) is an inhibitor of phosphodiesterase 5 (PDE5) that was shown to 
exhibit cardioprotective properties in various models of I/R injury. The ultimate objective of this 
project was to determine the efficacy of SNF as a cardioprotectant in our model of I/R. To do so, 
we employed H/R conditions that induced a significant level of injury. This result was observed 
when HL-1 cells were exposed to 2 hours of hypoxia induced with 0.5% O2 alone or followed by 
2 hours of reoxygenation. Although PDE5 was shown to be expressed in isolated ventricular 
cardiomyocytes from mice [64], we have confirmed the expression of PDE5 in murine atrial HL-
1 cardiomyocytes by western blotting (Figure 23A). To determine whether SNF can protect HL-
1 cells against hypoxia induced injury, HL-1 cells were exposed to 2 hours of hypoxia in 
presence of graded concentrations of SNF (0, 1.5 and 15 µM). In parallel, control cells were 
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Figure 23: A. Expression of PDE5 in HL-1 cardiomyocytes. HL-1 cell lysate was 
analyzed by western blotting for the expression of PDE5, the target of sildenafil. Human 
Umbilical Vein Endothelial Cells (HUVEC) lysate was used as a positive control. β-
Tubulin was used a loading control. B. Experimental protocols for Sildenafil studies. 
HL-1 cells were exposed to 2 hours of hypoxia (0.5% O2) alone (Hypoxia) or followed 
by 2 hours of reoxygenation where sildenafil (SNF: 0, 1.5, 15 µM) was added at the 
onset of hypoxia ((H+SNF)/R) or reoxygenation (H/(R+SNF)).  
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treated with similar doses of SNF and grown under normal conditions for an identical period. As 
previously shown, hypoxia induced a 3.6-fold increase in the percentage of Trypan blue positive 
cardiomyocytes in comparison to control conditions (Figure 24A). The presence of 15 µM SNF 
during hypoxia significantly limited the occurrence of cell death as the number of dead cells was 
increased only by 2-fold compared to control. A lower dose of SNF (1.5 µM) had no effect on 
hypoxia-induced cell death. Interestingly, SNF had an opposite effect on the viability of cells 
grown under normal conditions as a dose of 15 µM induced a slight increase in cell death. These 
results suggest that high dose of SNF (15 µM) seems to be beneficial to hypoxic cardiac cells. 
The effect of SNF on apoptosis was also examined by flow cytometric analysis of Annexin V-PI 
labeled cells (Figure 24B). As previously shown, hypoxia induced an increase in cell death with 
no effect on the basal level of early apoptosis. These outcomes were not altered by the presence 
of SNF in hypoxic cultures. However, the percentage of early apoptotic cells in healthy cultures 
was significantly decreased by SNF treatment (15 µM). Altogether, these results suggest that 
high doses of SNF may be cardioprotective against hypoxia.  
Next, we sought to determine whether SNF could protect cardiac cells against injury 
induced by 2 hours of hypoxia followed by 2 hours of reoxygenation. Two SNF treatment 
regimens were tested, SNF (0, 1.5, 15 µM) was applied at the onset of hypoxia or reperfusion. 
The rationale behind this approach is that an infarct-reducing agent can be applied at different 
times depending on the clinical situation I/R occurs. In patients undergoing cardiac surgery, the 
cardioprotective agent can be applied before or at the onset of the ischemic event (e.g. addition 
of the drug in the cardioplegic solution). In contrast, patients who suffer an acute myocardial 
infarction can only be treated by applying the drug at reperfusion. As previously shown, the level 
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Figure 24: Effect of sidenafil on hypoxia-induced cardiac cell death. HL-1 cells were 
exposed to 2 hours of hypoxia (0.5% O2) in presence of SNF (0, 1.5, 15 µM). Control 
cells were treated with similar concentrations of SNF and grown under normal conditions 
for an identical period of time. A. Trypan blue exclusion. The percentages of cell death in 
relation to controls (healthy cells) were represented graphically as mean ± SEM from 
three independent experiments. **p<0.0001, #p<0.01 (vs. Control) and **p<0.0001 (vs. 
untreated hypoxic cells) by One-Way ANOVA. B. Flow cytometric analysis of 
AnnexinV-PI stained cells. The percentages of dead cells (UL+UR) and early apoptotic 
cells relative to control levels were represented graphically and expressed as mean ± SEM 
from three independent experiments. **p<0.0001, *p<0.001, +p<0.05 (vs. Untreated 
Control) by One-Way ANOVA.  
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Figure 25: Effect of sildenafil on cardiac cell death elicited by hypoxia-
reoxygenation. HL-1 cells were exposed to 2 hours of hypoxia (0.5% O2) followed by 2 
hours of reoxygenation (H/R). SNF (0, 1.5, 15 µM) was added at the onset of hypoxia 
[(H+SNF)/R] or reoxygenation [H/(R+SNF)]. Control cells were treated with similar 
concentrations of SNF and grown under normal conditions for an identical period of time. 
A. Trypan blue exclusion. The percentages of cell death in relation to controls (healthy 
cells) were represented graphically as mean ± SEM from three independent experiments. 
**p<0.0001 (vs. H/R) by One-Way ANOVA. B. Flow cytometric analysis of AnnexinV-
PI stained cells. The percentages of dead cells (UL+UR) and early apoptotic cells relative 
to control levels were represented graphically and expressed as mean ± SEM from three 
independent experiments. **p<0.0001, *p<0.001, #p<0.01 (vs. H/R) by One-Way 
ANOVA. 
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of cell death induced by hypoxia was significantly reduced following 2 hours of reoxygenation 
as it reached ~180% of controls. This effect was accompanied by a 3-fold increase in the 
population of early apoptotic cells. The presence of SNF during hypoxia had no effect on the 
overall level of cell death following 2 hours of reoxygenation as assessed by both Trypan blue 
and PI staining (Figure 25). However, the level of early apoptosis was significantly decreased by 
SNF in a dose-dependent manner, indicating that the application of SNF at the onset of hypoxia 
limited the activation of apoptosis during the first two hours of reoxygenation. Conversely, the 
administration of SNF (1.5 and 15 µM) at the onset of reoxygenation resulted in a significant 
increase in cell death compared to untreated H/R cells (Figure 25). This effect was accompanied 
by a slight, though significant, decrease in the population of early apoptotic cells. This result 
suggests that SNF may accelerate the progression of early apoptotic cells to later stages of the 
apoptotic program. Thus, the application of SNF during reoxygenation may be detrimental to 
cardiac cells. Taken together, these results suggest that the presence of SNF during hypoxia may 
protect cardiac cells against hypoxia-induced cell death and decreases the occurrence of 
apoptosis during reoxygenation in a dose-dependent manner. A dose of 15 µM SNF was more 
effective in protecting cardiac myocytes against H/R-mediated injury. Conversely, the addition 
of SNF during reoxygenation exacerbated H/R-induced cardiac injury. 
 
3.3.2. The modulation of autophagy by sildenafil during hypoxia-reoxygenation 
The effect of SNF on autophagy during myocardial I/R injury has never been studied. 
Thus, we sought to determine how SNF could affect the autophagic response of HL-1 cells in our 
model. To this end, HL-1 cardiac cultures were exposed to 2 hours of hypoxia and 
simultaneously treated with increasing concentration of SNF (0, 1.5, 15 µM). We have examined  
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Figure 26: Effect of sildenafil on autophagy in hypoxic cardiac cells. HL-1 cells were 
exposed to 2 hours of hypoxia (Hypoxia, 0.5% O2) in presence of SNF (0, 1.5, 15 µM). 
Control cells were treated with similar doses of SNF and grown in normal conditions for 
the identical period of time. Baf A1 (25 nM) was absent (-) or present (+) throughout 
hypoxia. Autophagy was assessed by LC3 Western blotting and actin was used as a 
loading control. The ratio LC3-II/Actin were determined by densitometry analysis of the 
immunoreactive bands and represented graphically as mean ± SEM from four independent 
experiments. **p<0.0001, *p<0.001, #p<0.01 (vs. Untreated Control) and p<0.05 (vs. 
Untreated Hypoxia) by One-Way ANOVA. 
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the profiles of LC3 processing in the absence and presence of 25 nM Baf A1. As documented in 
Figure 26, SNF had no significant effect on the basal level of autophagy in healthy HL-1 cells. 
As previously shown, hypoxia induced a partial inhibition of autophagy in HL-1 cells as judged 
by the decrease in LC3-II accumulation in comparison to control conditions. This effect was 
enhanced when SNF (15 µM) was present during hypoxia, suggesting that SNF limited 
autophagy in hypoxic cells. Next, we investigated the effect of SNF on autophagy in HL-1 cells 
exposed to 2 hours of hypoxia followed by 2 hours of reoxygenation. SNF (0, 1.5, 15 µM) was 
added either at the onset of hypoxia or reoxygenation. The results shown in Figure 27A indicate 
that under normal conditions, SNF significantly increased the level of LC3-II accumulation in a 
dose-dependent manner, suggesting that SNF induced autophagy in HL-1 cells. The exposure of 
HL-1 cells to 2 hours of hypoxia followed by 2 hours of reoxygenation markedly reduced the 
accumulation of LC3-II associated with the reoxygenation period. These observations are in line 
with the results obtained from the reoxygenation time course experiment. The presence of SNF 
throughout hypoxia induced a significant increase in the accumulation of LC3-II during 
reoxygenation in comparison to untreated H/R cells. This effect was more pronounced with SNF 
at a dose of 1.5 µM. However, the SNF-induced increase in LC3-II accumulation remained lower 
than control cells. These results suggest that SNF limited the inhibition of autophagy induced by 
H/R in cardiac cells. The addition of SNF at the onset of reoxygenation resulted in a different 
profile of autophagy in cardiomyocytes exposed to H/R. As seen in Figure 27B, the level of 
LC3-II accumulation in HL-1 cardiac cells exposed to H/R was not altered by the presence of 
SNF during reoxygenation. However, both concentrations of SNF induced a significant increase 
in the instantaneous level of LC3-II. Since Baf A1 treatment did not enhance the accumulation of 
LC3-II, these results suggest that SNF, when present during reoxygenation, caused an inhibition 
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Figure 27: Effect of sildenafil on autophagy in cardiomyocytes exposed to hypoxia-
reoxygenation. HL-1 cells were exposed to 2 hours of hypoxia (0.5% O2) followed by 2 
hours of reoxygenation. SNF (0, 1.5, 15 µM) was added at the onset of hypoxia [A, 
(H+SNF)/R] or reoxygenation [B, H/(R+SNF)]. Control cells were treated with similar 
doses of SNF and grown in normal conditions for identical periods of time. Baf A1 (25 
nM) was absent (-) or present (+) throughout reoxygenation. Autophagy was assessed by 
LC3 Western blotting and actin was used as a loading control. The ratio LC3-II/Actin 
were determined by densitometry analysis of the immunoreactive bands and represented 
graphically as mean ± SEM from four independent experiments. **p<0.0001, #p<0.01 
(vs. Untreated Control) and p<0.001, 0.001, 0.05 (vs. Untreated H/R) by One-Way 
ANOVA. 
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of autophagy in reoxygenated HL-1 cells. Interestingly, the level of autophagy was also 
significantly decreased in healthy cells treated with SNF as judged by the reduced accumulation 
of LC3-II. Altogether, our results demonstrate that depending on its treatment regimen, SNF 
exerted antagonistic effects on autophagy in HL-1 cells during H/R. The administration of SNF 
during hypoxia induced autophagy during reoxygenation and this effect was maximal with a 
dose of 1.5 µM. In contrast, autophagy was further inhibited by SNF when added at the onset of 
reoxygenation. This effect was higher with a dose of 15 µM. 
 
3.3.2. The effect of sildenafil on cardiac energetics during hypoxia-reoxygenation 
To gain some insights into the mechanism employed by SNF to mediate its effects on cell 
death and autophagy during H/R, we sought to examine the effect of SNF on the bioenergetic 
status of cardiac cells during H/R. To this end, HL-1 cells were exposed to 2 hours of hypoxia in 
presence of graded concentrations of SNF (0, 1.5, 15 µM) and the ATP levels were measured. 
The results shown in Figure 28 indicate that SNF (15 µM) significantly limited the ATP 
depletion induced by hypoxia in HL-1 cells. The ATP levels in SNF-treated hypoxic cells 
reached approximately 30% of controls (vs. 10% of controls in hypoxic cells). This result 
suggests that SNF may partially protect cardiac cells from the deleterious metabolic effects of 
hypoxia. Next, we have examined the effect of SNF on the replenishment of the intracellular 
ATP stores during reoxygenation. Thus, HL-1 cells were exposed to 2 hours of hypoxia followed 
by 2 hours of reoxygenation, and SNF (0, 1.5, 15 µM) was added at the onset of hypoxia or 
reoxygenation. As previously shown, reoxygenation induced an increase in ATP in hypoxic 
cardiomyocytes as the ATP level reached 20% of controls. However, SNF had no significant 
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Figure 28: Modulation of the bioenergetic status of cardiac cells exposed to hypoxia-
reoxygenation by Sildenafil. HL-1 cells were exposed to 2 hours of hypoxia (0.5% O2,) 
alone (H) or followed by 2 hours of reoxygenation (H/R). SNF (0, 1.5, 15 µM) was added 
at the onset of hypoxia [H+SNF, (H+SNF)/R] or reoxygenation [H/(R+SNF)]. Control 
cells were treated with similar concentrations of SNF and grown under normal conditions 
for an identical period of time. The levels of ATP were measured and expressed as 
percentages relative to controls. Values are expressed as mean ± SEM from three 
independent experiments. **p<0.0001 (vs. Untreated Hypoxic cells) by One-Way 
ANOVA.  
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effect on the rate of ATP replenishment during reoxygenation, regardless of its concentration and 
time of application.  
In summary, we have demonstrated the ability of SNF to protect cardiomyocytes against 
I/R injury in our model. The addition of SNF at the onset of hypoxia protected HL-1 cells against 
hypoxia-induced cell death and limited the occurrence of apoptosis during reoxygenation. These 
effects were maximal with a dose of 15 µM. In contrast, the administration of SNF at the onset of 
reoxygenation was detrimental to cardiac cells. Here, we report for the first time the effect of 
SNF on autophagy in a model of myocardial I/R injury. SNF (15 µM) limited the occurrence of 
autophagy in hypoxic cells. The presence of SNF during hypoxia attenuated the inhibition of 
autophagy in reoxygenated cells; this effect was maximal with a dose of 1.5 µM. In addition, the 
presence of SNF during reoxygenation further inhibited autophagy in a dose-dependent manner. 
While SNF significantly limited the ATP depletion induced by hypoxia, it has no effect on the 
rate of ATP repletion during reoxygenation.           
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CHAPTER 4 – DISCUSSION 
The pathogenesis of myocardial ischemia-reperfusion (I/R) injury involves complex 
molecular and cellular mechanisms that have deleterious repercussions on the functional 
integrity of the heart [9]. The deprivation of nutrients and oxygen (ischemia) is accompanied by 
a drastic depletion in ATP, acidosis and dysregulation of ionic homeostasis, which leads to an 
overload of intracellular calcium. While these events lead to the demise of cardiomyocytes, the 
extent of irreversible damage depends on the severity of the ischemic insult and the onset of 
reperfusion. Paradoxically, reperfusion exacerbates the cellular instability induced by ischemia. 
While the reintroduction of oxygen promotes the production of ATP, it also induces the 
generation of reactive oxygen species by a dysfunctional electron transport chain. The opening of 
the mitochondrial permeability transition pore induced by oxidative stress and calcium overload 
further compromises cellular energetics and leads to cell death. The mechanisms of ischemic 
myocardial death are complex and may be determined by factors such as the location, severity 
and duration of the ischemic insult. In addition, the degree of ATP depletion, a hallmark of 
ischemia, is a major determinant in the mode of cell death injured myocytes will undergo. In the 
infarct core, which is completely deprived in oxygen and energy, myocardial death is marked 
predominantly by necrosis. On the other hand, cardiac myocytes present in the peri-infarct 
penumbra, which is hypoxic and undergoes oxidative injury, die mainly by apoptosis. In the 
remote myocardium cells remain viable, although delayed cell death can occur via both necrosis 
and apoptosis. The process of autophagy has also been associated with myocardial I/R injury. 
However, its significance and the nature of its role are unclear. 
We have developed an in vitro model to study the process of autophagy in the 
experimental context of myocardial I/R injury.  For our model to be relevant to the ischemic 
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conditions encountered in vivo, ischemia was induced with 0.5% and 2.0% O2. In patients 
suffering from myocardial infarction, the occlusion of the coronary artery induces nearly 
complete ischemia in the risk area with subsequent irreversible damage. However, the peri-
infarct penumbra of the myocardium still obtains low levels of oxygen from the adjacent area 
through diffusion. The validity of this model was established by assessing the bioenergetic status 
of HL-1 cardiac myocytes and the extent of cardiac injury during both hypoxia and 
reoxygenation. As previously mentioned, myocardial ischemia is characterized by a drastic 
depletion in ATP. Previous studies have shown that in the heart the ATP levels decrease by 65% 
and 90% by 15 and 40 minutes of ischemia, respectively [76]. The oxygen supply is completely 
and abruptly disrupted during myocardial ischemia in vivo, whereas in our model the oxygen 
concentration is progressively decreased as the medium in the dishes equilibrates with the 
oxygen level present in the chamber (0.5% or 2.0% O2). Nonetheless, the level of ATP fell 
dramatically and was only 15% of normal by the end of the 2-hour hypoxic exposure irrespective 
of the oxygen concentration used (Figure 8A). While reperfusion promotes the replenishment of 
intracellular ATP stores, this process can be limited by damage caused to the mitochondria. 
Here, we report that the ATP content of hypoxic myocytes gradually increased during 
reoxygenation (Figure 8B). However, the restoration of ATP was not fully accomplished. In 
addition, the rate of ATP repletion was dependent on the degree of hypoxia. HL-1 cells exposed 
to hypoxia induced with 0.5% O2 exhibited lower levels of ATP at all time points during 
reoxygenation than hypoxic myocytes incubated in presence of 2.0% O2. The slow and 
incomplete re-energization of myocytes may be attributed to the presence of damaged 
mitochondria, which may be more prominent under lower hypoxic conditions.  
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AMPK acts as a sensor of energy and is activated in response to an elevated AMP to ATP 
ratio. AMPK is composed of three subunits, the catalytic α subunit and two regulatory subunits 
(β and γ). AMPK activity is regulated by several mechanisms [77-79]. In response to elevated 
intracellular AMP levels, AMPKα is activated by phosphorylation at Thr172 by the upstream 
family of AMPK kinases (AMPKK) such as LKB1. In addition, AMPK activity is regulated by 
conformational changes induced by the binding of AMP to the γ subunit. This interaction 
maintains AMPK in an activated state by preventing the dephosphorylation of Thr172 of 
AMPKα by protein phosphatases such as PP2C (protein phosphatase 2C). These regulatory 
mechanisms are antagonized by nanomolar concentrations of ATP [77-79]. In addition, 
phosphocreatinine was also shown to inhibit AMPK activity [80]. In our study, the activation 
status of AMPKα was examined by western blotting as an alternative and complementary 
indicator of the bioenergetic status of HL-1 cells during H/R. Our results demonstrated that the 
ATP depletion coincided with enhanced phosporylation of AMPKα phosphorylation in myocytes 
at all times during hypoxia (Figure 9A). In addition, the intracellular pool of AMPK present in 
hypoxic myocytes was fully activated. In turn, reoxygenation triggered a renormalization of 
AMPKα phosphorylation levels in HL-1 cells (Figure 9B). The temporal profile of AMPK 
activation in cardiomyocytes subjected to I/R has been previously described. Baron and 
colleagues have observed elevated levels of AMPKK and AMPK activity in isolated working rat 
hearts subjected to ischemia and in ischemic intact rat hearts. In perfused working rat hearts, 
AMPKK activity was increased by 3-fold after 1 minute and peaked by 5 to 20 minutes of low-
flow ischemia. While the accumulation of phosphorylated AMPKα was less rapid during the first 
2 minutes of ischemia, it reached a maximal level after 5 to 20 minutes of ischemia [81]. 
Furthermore, mouse hearts subjected to 30 minutes of ischemia exhibited elevated levels of 
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AMPKα activity, which were maintained during the first 30 minutes of reperfusion [82]. This 
effect was accompanied by a significant decrease in ATP and phosphocreatinine in the ischemic 
mouse heart. While the ATP level remained low during reperfusion, the phosphocreatinine 
content was renormalized. Cardiomyocytes rely on phosphocreatinine as a reserve for ATP. The 
levels of phosphocreatinine have not been evaluated in our model.  
While the experimental approach used to mimic ischemia and reperfusion in vitro 
established a repressed energetic state in HL-1 myocytes, it resulted in a mild level of injury. The 
extent of cardiac injury was assessed by measuring the level of cell death and early apoptosis in 
HL-1 cells over a time course of several hours (0 to 16 hours post-hypoxia). Cell death was 
measured by two complementary techniques Trypan blue staining and flow cytometric analysis 
of AnnexinV-propidium iodide (PI) labeled myocytes. The results indicated that the levels of 
hypoxia that were used induced a moderate increase in cell death (Figure 10). While cells 
continued to die during the first hours of reoxygenation, cell death progressively decreased and 
the percentage of cells undergoing early apoptosis increased concomitantly (Figure 11). 
Importantly, the extent of cell death was highly dependent on the degree of hypoxia. Hypoxic 
cardiomyocytes exposed to 0.5% O2 were more susceptible to death during both hypoxia and 
reoxygenation than cells exposed to 2.0% O2. The population of cardiomyocytes pre-exposed to 
0.5% O2 that was undergoing early apoptosis was increased and peaked at a later time point 
during reoxygenation (4 hours) than cells pre-exposed to 2.0% O2 (2 hours) (Figure 11B). 
Interestingly, the rate of ATP replenishment and the activation of early apoptosis occurred faster 
in HL-1 cells exposed to 2.0% than 0.5% O2. These results suggest an association between the 
availability in ATP and the occurrence of apoptosis during H/R. While our studies have focused 
on early apoptosis, it would be of interest to examine the profile of biochemical or morphological 
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markers of late apoptosis in order to determine whether the ATP level present in HL-1 cells 
during reoxygenation is sufficient for the completion of the apoptotic program. The extent of 
injury to HL-1 cells exposed to I/R has been documented by several groups. For instance, 
Hamacher-Brady and colleagues have reported a 3-fold increase in Bax activation, a hallmark of 
apoptosis, in HL-1 cells expressing GFP-Bax exposed to 2 hours of simulated ischemia (anoxia) 
followed by 5 hours of reoxygenation [57]. In a subsequent study, 2 hours of simulated ischemia 
(anoxia) followed by 12 hours of reoxygenation resulted in a 5-fold increase in the percentage of 
apoptotic HL-1 cells with condensed chromatin labeled with Hoechst 33342 [40]. In addition, 
Yitzhaki and colleagues have demonstrated that the levels of LDH release from HL-1 cells 
subjected to 2 hours of simulated ischemia (anoxia) were increased by 5-fold in comparison to 
controls. Subsequent reoxygenation resulted in a 6-fold increase in cells that accumulated 
propidium iodide uptake by 3 hours [58]. These studies have yielded inconsistent data and the 
extent of the contribution of necrosis and apoptosis to each phase of I/R remains to be clearly 
established. In addition, the variability in the experimental context makes a comparison of the 
levels of cardiac injury elicited by I/R observed in the aforementioned studies and our study 
difficult. In the aforementioned studies, ischemia was induced in HL-1 cultures in absence of 
oxygen (anoxia). Therefore, the severity of the ischemic insult, the type of cell death (necrosis, 
apoptosis) and the methodology used to assess the occurrence of cell death may represent 
confounding factors in the extent of cell injury observed in these models. In our model, the 
extent of cardiac injury was confirmed by two different techniques (Trypan blue and PI staining). 
In addition, Annexin V staining allowed us to refine our analysis of cell death by evaluating the 
percentage of cells that were actively undergoing apoptosis. Our findings clearly indicated that 
H/R induced injury of cardiac cells resulting in two types of populations: (i) cells that have been 
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irreversibly damaged and died, and (ii) cells that had initiated apoptosis during reoxygenation 
and may still be salavaged. The ratio of these populations was dependent on the severity of the 
hypoxic insult. Thus, the presence of these populations indicates that our model recapitulated 
ischemic myocardial injury in vivo.  
The in vitro model of I/R injury that has been described above was considered to be 
sufficiently faithful to the in vivo condition that the role of autophagy could be studied in 
cardiomyocytes. This model offers the advantage that it focuses on cardiac cells rather than a 
mixture of myocytes, endothelial cells, smooth muscle cells, fibroblasts and inflammatory cells. 
This is important because damage to cardiac muscle is the most crucial component of I/R injury. 
In addition, the use of two hypoxic conditions, rather than anoxia, should predict the response of 
tissue that surrounds the anoxic focus. The cardiomyocytes in this region are able to receive 
limited oxygen by diffusion and collateral circulation, and it seems probable that cells in this 
penumbra are most likely to recover, and understanding their response may lead to better 
therapies. Aside from facilitating the study of autophagy, the model can be used to evaluate 
therapeutic maneuvers that may preserve cardiomyocytes during I/R. As an example of this, the 
protective effect of sildenafil, an inhibitor of cGMP phosphodiesterase 5 (PDE5), has been 
studied.   
Autophagy is involved in the turnover of organelles and cytoplasmic proteins that are in 
excess or dysfunctional. This multi-step process is initiated with the formation of the 
phagophore. The latter elongates while engulfing cytoplasmic material targeted for degradation 
to form the autophagosome. The fusion of the autophagosome with the lysosome leads to the 
degradation of the autophagic vacuole content by lysosomal hydrolases. The degradation 
products (amino acids, lipids and sugars) are recycled for ATP production (Figure 2). Autophagy 
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is an energy-dependent process. ATP is required for the completion of all steps but also for the 
synthesis and activation (by phosphorylation) of the molecular effectors that compose the 
autophagy machinery. Autophagy is a double-edge sword as it can promote cell survival and lead 
to cell death (Programmed Cell Death type 2). Autophagy has been extensively studied in the 
experimental setting of myocardial I/R injury [40,57]. However, these studies have yielded 
conflicting results with respect to the magnitude of autophagy and the nature of its role during 
cardiac I/R injury. In our study, autophagy was examined by assessing the endogenous level of 
LC3-II by Western blotting in presence of Baf A1, an inhibitor of autophagosomes maturation 
and lysosomal degradation of LC3-II. We have established the temporal profile of autophagy in 
HL-1 cells exposed to hypoxia alone or followed by reoxygenation. Our results demonstrated 
that autophagy was significantly influenced by the severity of the hypoxia. Cardiac cultures 
exposed to 2.0% O2 exhibited a level of autophagy that was similar to healthy cells (Figure 12B). 
On the other hand, autophagy was partially inhibited in hypoxic myocytes exposed to 0.5% O2 
for 2 hours (Figure 12A). Autophagy is an energy-dependent process and surprisingly, hypoxic 
cells were able to sustain a basal level of autophagy despite the severe depletion of ATP. One 
role of autophagy is to provide the cell with new source of energy to survive periods of stress. 
Therefore, it is plausible that the process of autophagy was designed to unfold under drastic 
energetic constraints. However, the completion of autophagy may be impaired if the bioenergetic 
status of the cell is below a certain threshold. The modulation of autophagy in HL-1 myocytes 
during hypoxia appears to be oxygen-dependent. This notion is supported by the observation by 
Hamacher-Brady and colleagues [57] that autophagy was completely blocked in HL-1 cells 
subjected to 2 hours of simulated ischemia under anoxic conditions. ATP may also be a limiting 
factor for the successful completion of autophagy. The validity of this hypothesis was established 
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by introducing glucose instead of 2-deoxyglucose (2-DG, an inhibitor of glycolysis) in the 
ischemia buffer. This approach resulted in a significant attenuation of the ATP depletion induced 
by hypoxia (with 2-DG) (Figure 14) which coincided with an enhancement of autophagy in 
myocytes exposed to 1 and 2 hours of hypoxia induced with both, 0.5% and 2.0% O2 (Figure 15). 
These results indicate that the lack of energy impaired the autophagic response early during 
hypoxia. The degree of hypoxia had some repercussions on the development of the autophagic 
response during reoxygenation as well. Severely hypoxic myocytes exhibited low level of 
autophagy by 2 hours of reoxygenation (Figure 13A). This effect was delayed in cells pre-
exposed to 2.0% O2 as autophagy declined later (4 hours of reoxygenation) (Figure 13B). These 
results indicate that reoxygenation elicited a partial blockade of autophagy with a timing that was 
oxygen-dependent. Interestingly, the introduction of glucose during hypoxia resulted in an up-
regulation of autophagy, probably by promoting ATP production. However, the reintroduction of 
nutrients (glucose) to hypoxic cells should have increased the production of ATP and promoted 
autophagy during reoxygenation as well; however, it failed to do so. One possible explanation 
for the impairment of the autophagic response during both prolonged hypoxia (0.5% O2) and 
reoxygenation is the presence of damaged mitochondria, a pathological hallmark of I/R injury. 
The damage to the mitochondria during I/R results from the generation of reactive oxygen 
species (ROS) and the activation of the mitochondrial permeability pore transition. All of these 
events are predominant during reperfusion. Mitochondria are a major site of ROS production. 
Ischemia was shown to lead to the production of ROS [83], which is rapidly enhanced by 
reperfusion. Studies have consistently reported an excessive burst of ROS at the onset of the 
reperfusion [84-88]. The damage to components of electron transport chain is thought to be 
responsible for the ROS production during I/R injury. The slow and incomplete recovery of ATP 
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production that occurs during reoxygenation may result from the presence of dysfunctional 
mitochondria. In addition, we observed that the re-energization of hypoxic cells occurred at a 
faster rate in HL-1 cells exposed to 2.0% than 0.5% O2, suggesting that the extent of 
mitochondrial damage was greater under low hypoxic conditions (0.5% O2). Further studies are 
required to examine the extent of ROS production as well as the integrity and function of 
mitochondria in HL-1 cells exposed to H/R. Oxidative stress was previously shown to be an 
inducer of autophagy [89], but we found that autophagy was progressively inhibited during 
reoxygenation. Considering the interplay between the mitochondria and autophagy, it is likely 
that the presence of damaged mitochondria can limit autophagy. A recent study has provided 
strong evidence that the outer membrane of mitochondria can be a source of autophagosomal 
membranes, at least during starvation [28]. Although it has not been demonstrated that the 
mitochondrial outer membrane has such a role during ischemia in cardiomyocytes, this 
possibility cannot be excluded. Cardiac muscle is an aerobic tissue and has a large number of 
mitochondria while the endoplasmic reticulum, another possible source of autophagosomal 
membranes, is specialized for the regulation of intracellular calcium concentration. It is possible 
that hypoxia (0.5% O2) induces damage to the mitochondria and diminishes the ability of the 
outer membrane of mitochondria to spawn autophagosomal vesicles. This would ultimately 
impair the process of autophagy at the initiation step. In addition, cardiac myocytes have a high 
requirement in energy that is reflected by an abundant mitochondrial content. Therefore, 
myocytes certainly rely on mitophagy, a process whereby damaged mitochondria are targeted for 
degradation via autophagy, to maintain their functionality and viability. Hypoxic myocytes 
exposed to 0.5% O2 exhibited low level of autophagy and may consequently be unable to 
eliminate damaged mitochondria through mitophagy. Severe hypoxia may cause a vicious circle 
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between mitochondria and autophagy where damaged mitochondria may limit the generation of 
autophagosomal membranes, which in turn, can lead to an inhibition of autophagy (mitophagy) 
and enhance the presence of damaged mitochondria.    
While the lack of ATP and perhaps the increased presence of damaged mitochondria may 
limit autophagy during H/R, a dysregulation of signaling molecules that modulate autophagy 
may also contribute to this outcome. Thus, we have explored the activation and expression status 
of several key regulators of autophagy. Under conditions of nutrient and energy depletion, 
autophagy is stimulated through inactivation of mTOR, a negative modulator of autophagy. Our 
results showed that hypoxia induced a dramatic dephosphorylation of mTOR at Ser2448 with 
respect to control conditions (Figures 16a and 16b). The inhibition of mTOR in hypoxic 
cardiomyocytes could result from (i) the repression of the PI3-K/Akt pathway as indicated by the 
low level of Akt phosphorylation and/or (ii) the activation of AMPK in response to low ATP 
levels. The activation of AMPK was shown to protect cardiac cells against the injurious effect of 
ischemia and this effect was mediated by an induction of autophagy [46]. To our great surprise, 
the inhibition of mTOR did not coincide with an enhancement of autophagy in hypoxic 
cardiomyocytes, suggesting that other factors may thwart the action of mTOR and limit the 
occurrence of autophagy during hypoxia. The levels of phosphorylation of AMPKα, Akt and 
mTOR in hypoxic cells were differentially affected by reoxygenation. Western blotting analyses 
revealed that although reoxygenation induced a decrease in the degree of AMPKα 
phosphorylation, the latter remained elevated following 2 and 4 hours of reoxygenation (Figure 
9B). In addition, the level of phosphorylated mTOR remained normal throughout reoxygenation. 
Whereas the level of phosphorylation of Akt was elevated during the first 2 hours of 
reoxygenation and declined to reach control levels by 4 hours of reoxygenation. The positive 
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regulators of autophagy include Beclin 1 and ERK1/2. Beclin 1 (a homologue of Atg6) is 
involved in the initiation step of autophagy through its interaction with other proteins (Vps34, 
Vps15, and Atg14) that compose the Class III PI3-K complex. The interaction of Beclin 1 with 
the anti-apoptotic protein Bcl-2 inhibits autophagy via disruption of the PI3-K complex. Our 
results indicated that H/R had no effect on the level of expression of Beclin 1 (Figures 16, 16-
Bis, 17 and 17-Bis). However, it is possible that the activity of Beclin 1 on autophagy is inhibited 
through its interaction with Bcl-2. Further studies are required to test this hypothesis. The 
modulation of ERK1/2 activation in response to H/R was rather complex. The activation of 
ERK1/2 in response to amino acid depletion was shown to stimulate autophagy [32]. 
Surprisingly, the level of phosphorylated ERK1/2 was rapidly and drastically reduced during 
hypoxia (Figures 16a and 16b). When HL-1 cells were re-supplied with nutrients during 
reoxygenation, ERK1/2 phosphorylation was enhanced by 1 hour and declined thereafter to 
levels lower than controls (Figures 17a and 17b). This profile is consistent with a transient 
activation of ERK1/2 during reoxygenation. Studies have shown that ERK1/2 displayed a 
distinct temporal profile of activation according to its cellular function. The sustained activation 
of ERK1/2, which lasts more than 12 hours, is thought to be involved in cell differentiation and 
cell death. Whereas a transient activation of ERK1/2 is considered to lead to cell proliferation 
and cell survival. Therefore, the possibility that ERK1/2 could promote the survival of myocytes 
during reoxygenation cannot be excluded. Altogether, these results indicate a discrepancy 
between the activation status of these modulators of autophagy and the nature of the autophagic 
response elicited by reoxygenation as well. The renormalization of Akt and mTOR 
phosphorylation levels and the activation of AMPK triggered by reoxygenation did not coincide 
with the profile of autophagy. The disconnect between autophagy and the activation status of its 
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modulators may have several explanations. First, it is likely that these pathways were modulated 
to enhance autophagy during H/R but that this effect was countered by other events induced by 
hypoxia and/or reoxygenation such as the shortage of ATP and oxidative stress. Another 
possibility is that the lack of phosphorylation of Akt, mTOR and ERK1/2 was part of a chaotic 
response to ischemic ATP depletion and was not a regulatory event, but instead another form of 
injury. ATP may be a limiting factor for the activation of these kinases by their upstream 
effectors depending on their Km for ATP. Further studies are required to establish the profile of 
activation of upstream modulators and downstream effectors of Akt, mTOR and ERK1/2 in order 
to discriminate between these possibilities. In addition, it would be of interest to examine the 
activation profile of the hypoxia inducible factor 1α (HIF-1 α). Zhang and colleagues have 
shown that the activation of HIF-1 α by hypoxia induces mitophagy in mouse embryonic 
fibroblasts. In this case, mitophagy promoted cell survival by preventing the production of ROS 
[30].  
Interestingly, the residual autophagic activity present in both, severely hypoxic and 
reoxygenated myocytes was necessary to maintain their viability. The significance of autophagy 
during both hypoxia and reoxygenation was demonstrated by a treatment with 3-MA, an 
inhibitor of PI3-K including the class III PI3-K which is involved in the initiation step of 
autophagy. The addition of 3-MA to HL-1 cardiac cultures exposed to 2 hours of hypoxia 
significantly inhibited autophagy (Figure 18) and enhanced hypoxia-induced cell death (Figure 
19). The protective role of autophagy during hypoxia was further supported by the observation 
that the up-regulation of autophagy elicited by adding glucose instead of 2-DG in hypoxic HL-1 
cultures coincided with a significant reduction in cell death that nearly reached the level of 
healthy cells (Figure 20). This approach appears to be a good alternative to the use of rapamcyin. 
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This drug is commonly used to stimulate autophagy through its inhibitory action on mTOR, a 
negative modulator of autophagy. However, our results showed that mTOR was completely 
inhibited in hypoxic cardiomyocytes, thus limiting the use of rapamycin. Interestingly, our 
results indicate that the up-regulation of autophagy was more beneficial to the most hypoxic cells 
(i.e. exposed to 0.5% rather than 2.0% O2). So far, we have no explanation for this result. It is 
possible that besides the stimulation of autophagy, the introduction of glucose in HL-1 cells 
during hypoxia triggers additional molecular events that are protective and oxygen-dependent. 
While glucose limited hypoxia-induced cell death, it promoted the occurrence of early apoptosis 
in an oxygen-dependent manner. This result suggests that cardiomyocytes that were destined to 
die by necrosis entered the apoptotic program instead and thus may be salvaged. The presence of 
3-MA during the first or last two hours of a 4-hour reoxygenation period induced a further 
increase in cell death while inhibiting autophagy (Figures 21 and 22). Moreover, the portion of 
early apoptotic cells during hypoxia was not affected by 3-MA. However, the presence of 3-MA 
during reoxygenation resulted in an increase or a decrease in the percentage of myocytes 
undergoing early apoptosis depending on whether cells were exposed to 0.5% or 2.0% O2, 
respectively. This effect of 3-MA may be explained by the ability of 3-MA to accelerate the 
progression of the apoptotic program. In the case of 0.5% O2, cells that were not apoptotic may 
have become early apoptotic while myocytes exposed to 2.0% O2 were already in early apoptosis 
and progressed through a later stage. Complementary studies aiming at examining markers of 
late apoptotic stages are required to test this possibility. Altogether, these findings suggested that 
the autophagic response of HL-1 cells subjected to hypoxia alone or to H/R exerted a protective 
effect against injury. Given the lack of specificity of 3-MA, which can also inhibit the class I 
PI3-K, it is possible that the increase in cell death reported here may be due to adverse effects of 
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the drug. We have shown that under normal conditions 3-MA had very little effect on HL-1 cells 
viability. The possibility that this effect can be enhanced under stressful conditions cannot be 
excluded. Nevertheless, the validity of our findings can be partly supported by several studies 
that have demonstrated the effect of 3-MA on cardiac cell death in an in vitro model of I/R 
injury. Hamacher-Brady and colleagues have documented the cardioprotective effect of 
autophagy against sI/R on several occasions. They have demonstrated that pre-treatment with 3-
MA of HL-1 cells exposed to 2 hours of simulated ischemia followed by 1.5 and 3 hours of 
reperfusion sensitized HL-1 cardiac cells to sI/R-induced apoptotic cell death [40,57]. In 
addition, the same effect was observed when autophagy was inhibited by wortmannin, down-
regulation of Beclin 1 or over-expression of Atg5K130R (a dominant-negative mutant of Atg5). 
While these findings suggest that 3-MA may represent a reliable tool to inhibit autophagy, it is 
essential to confirm our findings by using complementary approaches that target specific 
effectors involved in the initiation step of autophagy.  
 Another objective of this project was to evaluate the protective effect of therapeutic 
agents in relationship to autophagy in our model. We chose to test Sildenafil citrate (SNF) as this 
inhibitor of PDE5 was shown to exhibit cardioprotective properties in various models of I/R 
injury. The administration of SNF as a pre-treatment was shown to reduce myocardial infarct 
size in rabbits [63,90], mice [61], dogs [91], and rats [92]. In addition, the effect of SNF on 
autophagy has never been reported. SNF is currently used to treat patients with erectile 
dysfunction and pulmonary hypertension. The inhibition of PDE5, an enzyme that catalyses the 
degradation of cyclic guanosine monophosphate (cGMP) leads to the accumulation of cGMP, 
which, in turn, causes vasodilatation. PDE5 is highly expressed in a large variety of tissues 
including platelets and smooth muscle of the systemic vasculature. The presence of PDE5 in 
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cardiomyocytes is controversial. However, the expression of PDE5 in the left ventricle and 
isolated cardiomyocytes from dog [93] and mouse [64] as well as hypertrophied human left and 
right ventricles [94] has been reported. HL-1 is a murine atrial cell line and we have 
demonstrated by western blotting that these cells express PDE5 (Figure 23A). Here, we 
highlighted the complexity of the cardioprotection afforded by SNF against cardiac I/R. To 
evaluate the therapeutic properties of SNF in our H/R model, we used different doses of the 
PDE5 inhibitor (1.5 and 15 µM) and different treatment regimens, where SNF was applied at the 
onset of hypoxia or reoxygenation. The rationale for this approach is that myocardial I/R injury 
is encountered during several situations including acute myocardial infarction and cardiac 
surgeries. Therefore, the time/phase of administration of an infarct-reducing drug will vary 
depending on the clinical context. In acute myocardial infarction patients, the only modality of 
treatment is to apply the cardioprotective agent at the onset of reperfusion. In contrast, in patients 
undergoing cardiac surgery, the damage elicited by I/R can be prevented or limited by applying 
the drug before or at the onset of ischemia (e.g. addition of the drug to the cardioplegic solution). 
Thus depending on its mechanism of action and dose, a drug may be more efficient in protecting 
the heart against I/R injury when administered before or at the onset of ischemia or at the onset 
of reperfusion. We showed that a high dose of sildenafil (15 µM) efficiently protects 
cardiomyocytes against necrosis following hypoxia as evidenced by the significant decrease in 
trypan blue positive cells (Figure 24). To our great surprise, no cardioprotection was observed 
with lower doses (0.15 and 1.5 µM). Paradoxically, SNF (15 µM) slightly induced cell death 
under normal conditions. These results suggest that the protection of hypoxic cells afforded by 
SNF may be associated to pathological events triggered by hypoxia. The absence of these events 
in healthy cells may result in an antagonistic effect of SNF. While we clearly demonstrated that 
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SNF was beneficial to cardiac cells during hypoxia, the effect of SNF against H/R injury was 
complex. The addition of SNF at the onset of hypoxia had no significant effect on the level of 
cell death during reoxygenation. However, it caused a dose-dependent reduction of the 
percentage of cells actively undergoing early apoptosis during reoxygenation (Figure 25). This 
result suggests that SNF may either prevent the activation of the apoptotic program and therefore 
protect cardiac cells against H/R-induced apoptosis, or induce a different type of cell death. The 
former possibility is more likely as our finding is, to a certain extent, consistent with previous 
observations made by Das and colleagues. They showed that SNF (1, 10 µM) pre-treatment of 
isolated mouse ventricular myocytes prior to 40 minutes of simulated ischemia (1.0-2.0% O2) 
and 1 or 18 hours of reperfusion reduced both necrosis and apoptosis [64,65]. Here we report for 
the first time the effect of SNF administration at the onset of reperfusion in cardiac cultures. 
Strikingly, the addition of SNF at the onset of reoxygenation was detrimental to cardiac cells 
exposed to H/R. Indeed, SNF markedly enhanced H/R-induced cell death, irrespective of its dose 
(Figure 25). This effect was concomitant with a decrease in early apoptotic cells, presumably 
resulting from a rapid progression of the apoptotic program mediated by SNF. These findings 
clearly demonstrated and emphasized the importance of implementing different treatment 
regimens when evaluating the efficiency of a cardioprotective agent in the experimental context 
of I/R. Similar antagonistic effects of SNF, associated to its dose and time of application, on the 
autophagic response of HL-1 cells exposed to both H/R were observed in this study. We have 
demonstrated that autophagy was partially inhibited in hypoxic cells and that this effect was 
enhanced when a high dose of SNF (15 µM) was added at the onset of hypoxia (Figure 26). This 
effect may stem from two possible phenomena. We have shown a pro-survival role of autophagy 
during hypoxia. Consistent with this, the inhibition of autophagy mediated by 15 µM SNF should 
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consequently increase cell death. However, our results demonstrated that the same dose of SNF 
protected HL-1 cells against hypoxia-induced death. The second explanation, which is more 
likely, is that the presence of SNF at the onset of hypoxia may trigger a protective mechanism 
that limits the need of hypoxic cardiac cells to increase their autophagic response. In addition, 
the same dose of SNF limited the intracellular ATP depletion induced by hypoxia (Figure 28), 
suggesting that SNF protected cardiomyocytes against the metabolic stress elicited by hypoxia. 
Altogether, these findings strongly support a cardioprotective effect of SNF against the injurious 
effects of hypoxia and that this effect is mediated presumably by the ability of SNF to protect the 
mitochondria. We have also found that depending on the treatment regimen, SNF exerted 
opposite effects on autophagy in HL-1 cells during reoxygenation. When the drug was added 
during hypoxia, it increased autophagy and the maximal effect was observed with a dose of 1.5 
µM (Figure 27A). In contrast, the addition of the drug at the onset of reoxygenation resulted in 
an inhibition of autophagy, which was maximal with 15 µM SNF (Figure 27B). We have shown 
that autophagy was protective during reoxygenation as well. Thus, it is likely that the induction 
of autophagy in reoxygenated HL-1 cells elicited by the presence of SNF during hypoxia may be 
beneficial as it coincided with a decrease in early apoptosis. However, the induction of 
autophagy did not result in an increase of ATP in reoxygenated cells. This is likely due to 
oxidative damage elicited by the restoration of oxygen. In contrast, the SNF-mediated inhibition 
of autophagy in reoxygenated cells is likely to be detrimental to cardiomyocytes. Indeed, the 
inhibition of autophagy coincided with an increase in cell death. These results suggest that SNF 
may, partly, mediate its effects on H/R injury via autophagy. However, a direct link between the 
effect of SNF on the association of H/R injury and autophagy remains to be established. This can 
be achieved by using a gene-based approach to inhibit the initiation of autophagy in HL-1 cells 
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(e.g. down-regulation of Atg5 or Atg12 expression) and study the effects of SNF on H/R injury 
in absence of autophagy. Here, we have also shown that SNF had no significant effect on the rate 
of ATP replenishment during reoxygenation, regardless of its concentration or time of 
application (Figure 28). Therefore, the cardioprotective and pro-autophagic effects of SNF 
during H/R may involve other mechanisms.  
Our findings strongly indicate that the effects mediated by SNF in HL-1 cells exposed to 
H/R are highly dependent on its dose. Several groups reported a dose-dependent effect of SNF 
on I/R-induced cardiac cell death. For example, the administration of low concentrations of SNF 
(20-50 nM) in isolated heart of rat prior to 20 minutes of ischemia and 30 minutes of reperfusion 
reduced myocardial infarct size. The cardioprotection was lost with higher concentrations of 
SNF (200 nM) [95]. In the same line of evidence, isolated perfused mouse hearts subjected to 30 
minutes of ischemia and 120 minutes of reperfusion were protected by 0.1 µM SNF when given 
for 10 minutes at reperfusion. However, lower (0.01 µM) or higher (1 or 10 µM) doses of SNF 
failed to reduce infarct size [67]. The aforementioned studies have been carried out in intact 
hearts. However, the presence of other cell types in the heart such as endothelial cells, which 
express PDE5 makes it difficult to assert that the cardioprotection resulted from the action of 
SNF in cardiomyocytes. 
 Importantly, it is likely that the effects of SNF on cardiac cell death, autophagy and 
cellular energetics in our model system are not PDE5-specific. Indeed, the concentrations used in 
our study are 10 to 100 times higher than the dose found in the serum of patients of 70 kg body 
weight after orally taking a 100 mg tablet of SNF (0.7 mg/kg, according to the drug manufacturer 
Pfizer). While this dose of SNF is known to specifically inhibit PDE5 activity, SNF may inhibit 
other classes of PDE at higher doses. The cardioprotective effect of SNF was shown to be 
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mediated by several pathways in cardiac cells (Figure 4). Thus, studies designed to explore these 
mechanisms are necessary to understand how SNF mediates its effects during cardiac I/R. The 
endpoint of PDE-5 inhibition is the increase in nitric oxide (NO) production. Although NO 
production was shown to occur during both ischemia and reperfusion, its role in the pathogenesis 
of cardiac I/R is highly controversial (for review [96]). Depending on its level of generation, NO 
can be either protective or detrimental to the heart during I/R. Excessive production of NO was 
shown to have deleterious effect during I/R as it can lead to mitochondrial dysfunction. 
Considering the mechanism of action of SNF, it would be of interest to evaluate the level of NO 
production in cardiomyocytes during I/R. In addition, the effect of SNF was shown to converge 
on the mitochondria, which plays a crucial role in the pathogenesis of I/R injury. Here, we 
demonstrated that high doses of SNF efficiently reduced cardiac cell death induced by hypoxia 
and reduced early apoptosis following H/R, provided the drug is administered at the onset of 
hypoxia. The administration of SNF at the onset of reoxygenation enhanced the injurious effect 
of reoxygenation. Therefore, we propose that SNF may represent a good therapeutic agent when 
as a cardioplegic solution component.  
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Autophagy has been implicated in the pathogenesis of myocardial ischemia-reperfusion 
(I/R) injury; however, it is not clear whether autophagy is beneficial or detrimental to cell 
survival. We hypothesized that autophagy is beneficial to cardiomyocytes during I/R and that the 
paucity of ATP may limit its occurrence. To test this hypothesis, we developed a model of 
ischemia (hypoxia) involving exposure of HL-1 murine atrial cardiomyocytes to two 
concentrations of oxygen (0.5% and 2.0%) and 2-deoxyglucose.  
Hypoxia, irrespective of the oxygen concentration, caused a dramatic drop in cellular 
ATP and an increase in the phosphorylation of AMPK (an indication of energy starvation),. The 
activation of the pro-autophagic AMPK coincided with an inactivation of mTOR and Akt in 
hypoxic myocytes. While these molecular events would be expected to lead to a stimulation of 
autophagy, we found that the level of autophagy remained at or near control levels under both 
conditions of ischemia. Autophagy was limited by the shortage in ATP as the presence of 
glucose instead of 2-deoxyglucose in the ischemia buffer increased ATP content and stimulated 
autophagy in hypoxic cells. In addition, cardiac cell death was significantly increased by 2 hours 
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of hypoxia, to a higher extent with 0.5% oxygen. Importantly, inhibition of autophagy by 3-
methyladenine increased hypoxia-induced cell death. In contrast, the stimulation of autophagy 
mediated by glucose coincided with a significant reduction in cardiac cell death following 
hypoxia. These results suggest that autophagy is beneficial to HL-1 cells during ischemia, but 
that the marked reduction in ATP limits the autophagic response. In turn, reoxygenation of 
hypoxic cells exposed to 0.5% or 2.0% oxygen caused a partial restoration of ATP levels, which 
coincided with an activation of apoptosis. Importantly, the rates of these events were dependent 
on the degree of hypoxia. Interestingly, the levels of phosphorylation/activation of AMPK, Akt 
and mTOR returned to basal levels in reoxygenated cells. However, autophagy was greatly 
compromised as cells pre-exposed to 0.5% and 2.0% oxygen exhibited low levels of autophagy 
after 2 and 4 hours of reoxygenation, respectively. As under ischemic conditions, the presence of 
3-methyladenine during reoxygenation enhanced cardiac cell death.  
In conclusion, we found that autophagy was differentially affected by the degree of 
hypoxia during both hypoxia and reoxygenation. The residual level of autophagy was essential to 
protect cardiomyocytes against the injurious effects of both hypoxia and reoxygenation, further 
validating our hypothesis. 
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